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CD157/bone marrow stromal antigen 1 (BST-1) is a 42-45kDa glycosyl 
phosphatidylinositol (GPI)- anchored glycoprotein expressed in both hematopoeitic 
and non-hematopoeitic cells.  Previous studies have shown that the expression of 
CD157 was up-regulated in bone marrow stromal cell lines derived from patients with 
rheumatoid arthritis.  Furthermore, its role in supporting the growth of pre-B cells has 
been demonstrated in knockout mice studies.  CD157 shares a significant homology 
of about 30% amino acid identity with CD38, a surface lymphocyte surface antigen. 
CD157 is a bi-functional ecto-enzymes possessing ADP-ribosyl cyclase and cyclic 
ADP-ribose hydrolase activities.  Cross-linking of CD157 with specific antibodies 
have resulted in tyrosine phosphorylation and dephosphorylation of selective proteins, 
suggesting a receptorial role of CD157.  We have shown that over-expression of 
CD157 in MCA102 cells results in tyrosine phosphorylation of focal adhesion kinase 
(FAK).  However, the majority of signaling molecules that are involved in CD157 
mediated tyrosine kinase pathway are yet to be identified.  Therefore, by identifying 
the interacting partner(s) of CD157 may help to elucidate the function of CD157 in 
vivo and in vitro.  Such information may be of therapeutic value as CD157 is known 
to be up-regulated in rheumatoid arthritis patients.  In this study, the human soluble 
CD157 was used as bait in yeast two-hybrid screening against Hela and B cell cDNA 
libraries.  It was found that alpha type 2 proteasome (prosome, macropain) subunit 
interacts with CD157.  In order to test the specificity of interaction, we later expressed 
a 74kDa CD157-Fc fusion protein (containing the human IgG1 Fc region) and 
proteasome-GST fusion protein for in vitro binding assay.  Western blotting results 
showed the interaction was intact in this GST pull down assay.  The specificity of the 
interaction of CD157 with proteasome was further characterized by over-expressing 
 ix
myc tag proteasome fusion protein in stable CD157-Fc CHO cell line for 
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1. Molecular characterization of CD157 
1.1 Identification of CD157 
CD157 was first identified in 1985 as Mo5, when a monoclonal antibody 
(mAb) was raised against an unknown antigen, by immunizing mouse with the human 
leukemia cells from a patient with acute monocytic leukemia (Todd III et al., 1985).  
It was also named as BP-3, a variably glycosylated cell surface protein (38-48kDa) 
that is selectively expressed on early B lineage cell and relatively mature myeloid 
lineage cells in mice (McNagny et al., 1988).  It was found that this protein is released 
from the surface of pre-B cells and macrophages by treatment with 
phosphatidylinositol specific phospholipase C (PI-PLC), suggesting a glycosyl 
phosphatidylinositol (GPI) linkage with the plasma membrane (McNagny et al., 1991).  
Two BP-3 cDNA clones which shared significant homology with genes encoding 
nicotinamide adenine dinucleotide (NAD) glycohydrolase of Aplysia californica and 
the CD38 antigens in mouse and human were isolated, suggesting that BP-3 molecule 
may be a relative of this nucleotidase family (Dong et al., 1994).   
In 1992, a human homologue of BP-3 was identified as BST-1 (bone marrow 
stromal cell antigen 1) (Kaisho et al., 1992).  It was discovered that in the bone 
marrow stromal cell lines derived from severe rheumatoid arthritis (RA) patients have 
an enhanced ability to support the growth of a pre-B-cell lines, DW34 as compared 
with stromal cell lines derived from healthy donors.  Therefore, in order to identify 
the unknown molecule that was involved in B-lineage cell growth, two monoclonal 
antibodies (mAbs), RF3 and SG2, against RA-derived BM stromal cell lines were 
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raised and cloned a cell surface molecule, designated as BST-1 (bone marrow stromal 
cell antigen 1) (Kaisho et al., 1994).   
The deduced amino acid sequence of BST-1 showed 33% identity with CD38.  
These findings informed that Mo5, BP-3 and BST-1 refer to the same molecule.  
Therefore, in the 6th Human Leukocyte Differentiation Antigen (HLDA) workshop, 
Mo5, BP-3 and BST-1 were named as CD157 (Ishihara et al., 1997).    
 
1.2. Cellular expression and tissue distribution of CD157 
In mouse, CD157 is expressed on normal pre-B and B cells in the bone 
marrow.  There are 35% of B cells in the circulation, 30% of the B cells in the spleen, 
and ≤ 20% of B cells in lymph nodes, peritoneal cavity and Peyer’s patches expresses 
CD157.  The subpopulation of CD157+ B cells in bone marrow and peripheral tissues 
displayed an immature phenotype (IgM+++IgD±) (McNagny et al., 1988).   
In human, CD157 is expressed on bone marrow stromal cell lines, synovial 
cell lines, human umbilical vein endothelial cells (HUVEC), follicular dendritic cell 
lines, myelomonocytic cell lines, peripheral granulocytes, monocytes, in vitro 
differentiated macrophages, all myeloperoxidase-positive bone marrow myeloid 
precursors but not non-myeloid cells in peripheral blood and bone marrow (Kaisho et 
al., 1994; Okuyama et al., 1996; Clark et al., 1995; Todd III et al., 1985).    
CD157 is expressed on brush borders of the intestinal epithelial cells, within 
collecting tubules of the kidney and on a subpopulation of reticular cells located in 
lymph nodes, Peyer’s patches and the white pulp areas of the spleen.  In contrast, 
reticular cells located in the thymus, bone marrow and splenic red pulp do not express 
the CD157 antigen (McNagny et al., 1991). 
The surface expression of CD157 on lymphoid progenitor cells appears prior to 
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the gene rearrangement of m heavy chain and TCRb chain (mouse).  In T lineage 
cells, the expression of CD157 is restricted to CD25+CD44- and CD25-CD44- 
fractions of CD3-CD4-CD8- (triple negative) T progenitors (Vicari et al., 1996).  In B 
lineage cells, the expression of CD157 is down-regulated at the stage of mature B cell 





















Figure 1: Expression profiles of CD157 on lymphocytes during development 
maturation.  CD157 is expressed at the early stages of B and T cells 
development but is sharply down-regulated once they become mature (Adapted 
from Ishihara et al., 1996) 
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1.3 Genomic structure of CD157 
The human CD157 cDNA encodes a protein consisting of 290 amino acids 
attached to a GPI-anchor.  The CD157 gene consists of nine exons and eight introns.  
The flanking region of the CD157 gene contained several potential binding sites for 
nuclear factors, nuclear factor κB  (NF-κB), p53, nuclear factor for IL-6 gene (NF-
IL6), cAMP response element binding protein (CREB), polyomavirus enhancer A 
binding protein (PEA3), E2A, CCAAT/enhancer binding protein (C/EBP), adaptor 
protein AP3 and AP2, specific protein 1 (SP1) and consensus sequence for γ –
interferon response element (γ–IRE) and interferon stimulated response element 
(ISRE) like element (Muraoka et al., 1996; Yang et al., 1990; Fujita et al., 1985; 
Faisst et al., 1992; Martin et al., 1988; Akira et al., 1992; Lenardo et al., 1989; El-
Deiry et al., 1992; Johnson et al., 1987; Sassone-Corsi, 1988; Jones et al., 1985).  
These elements suggest that CD157 gene could be up-regulated by events like 
inflammation and infection, DNA damage, whereas, the NF-κB and NF-IL6 binding 
sites may explain the increase level of CD157 in RA patients.   
The deduced amino acid sequence of CD157 has 33% homology with human 
CD38 and 26% homology with Aplysia ADP-ribosyl cyclase (Kaisho et al., 1994).  
Murine and rat CD157 shows 71% and 72% homology of amino acid sequence with 
human CD157, respectively (Itoh et al., 1994; Furuya et al., 1995).  The human 
CD157 gene was mapped to 4p15, which is the same for CD38 (Dong et al., 1996; 
Nakagawa et al., 1995).  Genomic structure analysis reveals the striking similarity 
between CD157 and CD38, indicating that CD157 and CD38 are evolved by gene 
duplications from an ancestral gene (Dong et al., 1996; Muraoka et al., 1996; Ferrero 
et al., 1997).   
The glycosylated CD157 has a molecular weight of 42-45kDa.  There are four 
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potential N-linked glycosylation sites (Asn-X-Ser/Thr) in CD157, Asn66, Asn95, 
Asn148 and Asn192 are essential for correct folding and functional activity.  As in site 
directed mutagenesis analysis, it was found that carbohydrates attached to Asn66, 
Asn148, Asn192 are necessary for CD157 secretion and Asn148 and Asn192 are needed 
for the cyclase activity (Yamamoto et al., 2001).  The positions of ten cysteine 
residues of CD157 are completely conserved among CD38 and the Aplysia ADP-
ribosyl cyclase.   
It was found that CD38 and its paralog CD157 map to the same 800kb restriction 
fragment in pulse-field gel electrophoresis, indicating that the two human ecto-
NADase genes are closely linked (Ferrero et al., 1999).  Furthermore, crystallographic 
studies of CD157 in ligand-free form and in complexes with five substrate analogues: 
nicotinamide, nicotinamide mononucleotide (NMN), adenosine 5’-O-(3-
thiotriphosphate) (ATPγS), nicotinamide 1,N6-ethenoadenine dinucleotide phosphate 
(ethenoNADP), 1,N6-ethenoadenine dinucleotide (ethenoNAD) were perfomed and 
observed that the structure of CD157 overall resembles that of Aplysia cyclase 
(Yamamoto et al., 2002).     
      
2. Biological function of CD157 
2.1 Pathophysiological roles of CD157 
Rheumatoid arthritis (RA) is characterized by chronic inflammation with 
infiltration of a variety of inflammatory cells, including those of myeloid origin as 
well as T and B lymphocytes into the affected synovium.  One feature of rheumatoid 
inflammation is local B cell activation and the production of large amount of 
immunoglobulin (Ig) (Smiley et al., 1968; Wernick et al., 1985).  It was observed that 
in severe RA cases, the serum CD157 was at concentrations 30-50 times higher than 
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those of healthy donors, suggesting a possible role of CD157 in the progression of the 
disease (Lee et al., 1996).   Also, the levels of CD157 expressed on rheumatoid 
arthritis-derived bone marrow stromal cell lines are higher than those derived from 
healthy donor (Kaisho et al., 1994).  This suggested the presence of abnormalities in 
the bone marrow microenvironment of rheumatoid arthritis patients.  It was reported 
several cases of complete remission of rheumatoid arthritis or psoriatic arthritis after 
bone marrow transplantation (Liu Yin and Jowitt 1992; Lowenthal et al., 1993).    
 
2.2 Cellular functions of CD157 
A CD157-deficient mice had been generated that exhibited a delay in the 
development of peritoneal B-1 cells and a corresponding increase in CD38 (low/-) B 
lineage cells in the bone marrow and spleen.  There was also a partial impairment of 
thymus-dependent and thymus-independent antigen-specific immune response in 
these knockout mice (Itoh et al., 1998).  Apparently, CD38-deficient mice showed an 
impairment of T-cell dependent antibody response as well (Cockayne et al., 1998).   
It was found that anti-CD157 mAb, IF-7 has a synergistic effect on anti-CD3-
induced growth of T progenitor cells, and facilitates the development of [alpha][beta] 
TCR+ cells in fetal thymic organ culture system (Vicari et al., 1996).  Furthermore, 
analysis with anti-murine BST-1 mAB G12 showed that the beginning of CD157 
expression on B and T cell progenitors coincides with the stage when the gene 
arrangement of immunoglobulin m and T cell receptor b chain, respectively (Ishihara 
et al., 1996).  These results indicate that CD157 not only has roles in B cell 
development and antibody production in vivo but also in T cell lymphopoiesis as well.   
Anti-CD157 mAb, Mo5 was found to block the phagocytic activity of neutrophils, 
activate the NADPH oxidase-catalyzed superoxide generation in U937 cells, and 
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inhibit the transepithelial migration of neutrophils in the apical-to-basolateral 
direction but not in the opposite direction in an in vitro experimental model 
(Malinowska et al., 1995; Colgan et al., 1995; Pfefferforn et al., 1995). 
 
2.3 Enzymatic activities of CD157 
The soluble ADP-ribosyl cyclase was discovered in an extract of sea urchin eggs 
and was purified from Aplysia californica ovotestis (Hellmich et al., 1991; Lee et al., 
1991).  Later, it was found in bacteria and Euglena (Karasawa et al., 1995 and 
Masuda et al., 1997), plant (Wu et al., 1997) and mammalian tissue (Rusinko et al., 
1989; Lee et al., 1993).  ADP-ribosyl cyclase catalyzes the synthesis of cyclic ADP-
ribose from NAD, and then cyclic ADP-ribose is hydrolyzed to ADP-ribose. Cyclic 
ADP-ribose is a second messenger that induces intracellular Ca2+ release through the 
ryanodine receptor independently of the IP3-mediated pathway (Galione et al., 1991; 






CD38 and CD157 are the two ADP-ribosyl cyclases that have been identified at 
the molecular level in mammalian tissues.  CD38 is a type II glycoprotein that 
consists of a small intracellular N-terminal tail, a transmembrane domain and a large 
enzymatically active C-terminal extracellular domain (Jackson et al., 1990).  CD157 
and CD38 both have ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities 
(Hirata et al., 1994).  However, as compared to CD38, a human lymphocyte surface 
               ADP-ribosyl cyclase 
NAD+     cyclic ADP-ribose (cADPR) + nicotinamide 
 
                            cADPR hydrolase 
cADPR + H2O     ADP-ribose (ADPR) 
 9
antigen, the specific enzymatic activities of CD157 are very low (Howard et al., 1993; 
Hirata et al., 1994).   
In the presence of Zn2+, CD157 showed optimal enzymatic activity in the range of 
pH 4.0 to 6.5; however, Cu2+ inhibited both cyclase and hydrolase activities of CD157 
(Hirata et al., 1994). It is unknown how the extracellularly produced cADPR 
functions intracellularly.  Two mechanisms are postulated; the membrane 
ectoenzymes may be internalized (Funaro et al., 1998) or they may possess channel or 
transporter properties (Franco et al., 1998).   
SNP-1, a 15mer peptide, was shown to inhibit ADP-ribosyl cyclase activity and 
cyclic ADP-ribose hydrolase activities of CD157 dose-dependently (Sato et al., 1999).  
However, it does not affect the CD38 enzymatic activity.  A region from amino acid 
residues 7-12 appeared to be critical for the SNP-1 binding to CD157.  The 
substitution of the first residue, His, to Ala led to a reduction in binding, suggesting 
that the N-terminal residue is crucial in enzymatic activity (Sato et al., 1999).  Site 
directed mutagenesis on four putative N-glycosylation sites of BST-1 has shown that 
carbohydrates attached to Asn148 and Asn192 are needed for the cyclase activity and 
the carbohydrate attached to Asn192 may be important for the hydrolase activity.  
Furthermore, it was found that Asn192 is conserved between BST-1 and CD38, 
indicating its importance for biological function (Yamamoto et al., 2001). 
 
2.4 Signaling property of CD157 
It was observed that cross-linking of CD157 with anti-CD157 on pre-T cells 
stimulated cell growth and proliferation (Vicari et al., 1996).  Inhibitor peptide SNP-1, 
isolated by random phage library was shown to inhibit ADP-ribosyl cyclase activity 
of CD157 in an uncompetitive manner (Sato et al., 1999).  All these studies provide 
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evidence that CD157 could function as a receptor being capable of generating signal 
transduction upon activation by agonist.   
U937 and THP-1 cells were used for cross-linking study of CD157 with 
polyclonal anti-CD157 antibody, which induces tyrosine phosphorylation of a 130kDa 
protein.  Cross-linking of CD157 expressed on CHO-CD157 transfectant also induces 
tyrosine phosphorylation of 130kDa protein, dephosphorylation of 100kDa protein, 
and growth inhibition (Okuyama et al., 1996).  Similar finding was also observed in 
MCA102/CD157, COS-7/CD157 and monocytes differentiated HL60 cells by vitamin 
D3 treatment (Hussain et al., 1999).  It was observed that CD157 mediated p130 
phosphorylation is ligand independent in recombinant CD157-expressing CHO, 
MCA102 and COS-7 cells but is ligand dependent in HL60 differentiated monocytes 
(mHL60).  The finding of ligand independence p130 phosphorylation in CHO/CD157 
by Hussain was contradictory to the finding of Okuyama, where ligand dependent 
mechanism was shown in the CHO/CD157 cells.  It was speculated that the ligand 
independence of the p130 phosphorylation in CHO/CD157 cells observed by 
Huassain might have resulted from high CD157 densities on the cell surface, which 
could overcome the dependence of ligand to initiate phosphorylation. 
Subsequently, the p130 tyrosine phosphorylated protein was identified as focal 
adhesion kinase (FAK or pp125FAK), a cytoplasmic protein that play a role in 
integrating signals in regulating cell functions.  FAK undergoes phosphorylation at 
Tyr-397 and Tyr-861 in CD157 stable transfected MCA102 cell lines 
(MCA102/CD157) (Liang et al., 2001).  It was demonstrated that CD157, 
independent of antibody crosslinking, undergoes dimerization with disulfide bond 
formation and localization in caveolae in CHO/CD157 and MCA/CD157 fibroblast.  
However, the native CD157 induced in mHL-60 cells remains a monomer form.  The 
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structural integrity of caveolae is required for the association of CD157 with caveolin 



































Functional expression of human CD157-Fc recombinant 



















CD157 is a GPI-anchored cell surface glycoprotein. Cross linking with anti-
CD157 antibodies has been shown to induce phosphorylation and dephosphorylation 
of selective proteins. Thus, it is postulated that CD157 functions as a receptor.  
Identification of the interacting proteins with CD157 would help to elucidate the 
function of the receptor.  Therefore, a soluble CD157 in the form of fusion protein 
containing a tag at the NH2 or COOH terminus is needed to ease for the screening of 
interacting proteins in the subsequent experiments.   
An ideal tag is one which i) is unlikely to interfere with protein folding, ii) 
leads to enhanced secretion in appropriate cells, iii) can be used for purification and 
iv) can be used for detection of the recombinant protein of interest in a variety of 
assays.  The Fc region of human IgG1 fused at the COOH-terminus fulfills all of these 
criteria; therefore, was used as a tag to generate the soluble recombinant CD157-Fc 
fusion protein.   
Mammalian expression system is chosen as the expression system to produce 
the recombinant protein.  This is because the origin of the gene (CD157) is from 
eukaryote (human).  In mammalian expression system, proteins undergo post-
translational modifications including glycosylation and disulfide-bridge formation 
when directed to the secrectory pathway. 
Primers were designed to amplify a human CD157 segment by PCR, such that 
the sequence for the N-terminal secretion signal will be included but the C-terminal 
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GPI signal would be excluded from the expressed recombinant CD157.  Another set 
of primers were used to amplify the Fc region from Human IgG in order to fuse with 
the CD157.  Cloning of such CD157-Fc was carried out and subsequently used for 
transfection in mammalian cell lines.  Protein purification was performed by 
collecting the culture medium from the transfected cell lines (CHO), concentrated and 
the medium was subjected to affinity purification using Fc- agarose beads.  The 
purified protein was then applied to SDS-PAGE, Western blot detection and 
enzymatic assay to verify the functionality of the recombinant protein (CD157-Fc). 
 
1.2 Materials 
1.2.1 Oligonucleotides Synthesis 
All oligonucleotides were synthesized from PROLIGO Primers & Probes. 
SHUCD157  5’ ccgaattcaccatggcggcccaggggtgc 3’ 
ASHUCD157  5’ gatttgggctctcctggaccttctgtataaagacttggg 3’ 
SHUFC  5’ ggtccaggagagcccaaatcttgtgacaaaactc 3’ 
ASHUFC  5’ ccggtacctcatttacccggagacaggg 3’ 
 
1.2.2 Enzymes and chemicals 
PCR reaction buffer, restriction enzyme, DNA marker, 6X loading dye and T4 ligase 
were purchased from Promega, USA.  Media components for bacterial culture were 
obtained from Sigma-Aldrich, MO and Oxoid, UK. 
 
1.2.3 cDNA template 
The human CD157 cDNA clone was provided by Toshio Hirano, Osaka University 
Medical Institute, Japan.  ESD1 heavy chain cDNA cloned in vector pSPORT1 was a 
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kind gift from Trevor Paterson from Department of Veterinary Pathology, University 
of Edinburgh, UK. 
 
1.2.4 Plasmid 
pGEMT-easy vector with TA cloning site was obtained from Promega, USA.  PXJ41 
expression vector was obtained from Institute of Molecular Biology (IMCB), NUS 
(Zheng et al., 1992). 
 
1.2.5 Bacterial strain 
The cloning experiments involving bacterial was carried out in the Escherichia coli.  
The genotype of the E.coli strain used is DH5α : supE44 lacU169 (Φ80lacZ∆M15) 
hsdR17 recA1 endA1 gyrA96 thi-1 relA1 (Sambrook et al., 1989). Stocks were 
maintained at -80°C in 15% glycerol. 
 
1.2.6 Cell line 
CHO cell line was obtained from ATCC, USA. 
 
1.2.7 Cell culture medium 
RPMI, DMEM, 10X PBS were obtained from NUMI, NUS.  200mM L-glutamine and 
penicillin/streptomycin were purchased from Life Technologies, USA. 
 
1.2.8 Extraction kit 
QIAquick Gel Extraction Kit and Qiagen Plasmid Midi Kit were purchased from 
Qiagen, Germany.  Wizard plus SV Minipreps DNA purification System was 
purchased from Promega, USA. 
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1.2.9 Centrifuge 
Small scale high speed centrifugation was carried out on microcentrifuge purchased 
from Eppendorf, Germany. 
 
1.2.10 Thermal Cycler 
PCR was carried out in a PCR Express Thermal cycler from ThermoHybaid, Italy.  
 
1.2.11 Cell Culture Incubator 
CO2 incubator was purchased from Binder, Germany. 
 
Sources of other reagents will be specified appropriately. 
 
1.3 Methods 
1.3.1 Polymerase Chain Reaction 
Reagents 
DNA template    = 1µL (1ng) 
Forward primer   = 1µL (1µM) 
Reverse primer   = 1µL (1µM) 
dNTPs mix (10mM each of dNTP) = 1µL (0.2mM each) 
25mM MgCl2    = 3µL (1.5mM) 
10 X reaction buffer    = 5µL (1X) 
Nuclease free water   = 37.5µL 
Taq polymerase (5u/µL)  = 0.5µL (0.05u/µL) 
Total     = 50µL 
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Procedure 
PCR was performed in the thermal cycler in the following PCR program: 
1.94°C – 1 minute 
2.94°C – 30 seconds 
3.50°C -60°C -30 seconds 
4.72°C - 1 minutes 
repeat step 2 to step 4 for 30 cycles 
5. 72°C – 10 minutes 
6.4°C 
This program can be adjusted dependent on the size of the amplified DNA and the 
primers used. 
 
1.3.2 Agarose gel electrophoresis of DNA 
Reagents 
1. SeaKem LE agarose was purchased from BioWhittaker Molecular 
Applications, USA. 
2. TAE 50X buffer (1 liter): 242g Tris base, 57.1ml glacial acetic acid, 100ml 
0.5M EDTA, pH8.0. Adjust to pH 7.2 and bring the final volume to 1 liter 
with distilled water.  
3. 1kb DNA marker 
4. 6x DNA loading buffer: 10mM Tris-HCl, pH7.5, 50mM EDTA, 10% Ficoll® 
400, 0.25% Bromophenol Blue, 0.25% Xylene Cyanol FF, 0.4% Orange G. 





Minigel apparatus was set up as recommended by the manufacturer.  Required 
amount of agarose was weighed out and added to appropriate amount of TAE 1X 
buffer in an Erlenmeyer flask.  Mixture was heated on a hot plate for the agarose to 
dissolve.  Solution was cooled to 50-60°C and gel was poured.  Gel was allowed to 
form completely.  Comb from the gel was removed and placed in the electrophoresis 
chamber and a sufficient volume of TAE 1X buffer to just cover the surface of the 
gel.  DNA samples were mixed with 1/6 of the 6x DNA loading buffer and loaded 
into the wells.  Gel apparatus was connected to an electrical power supply and an 
appropriate voltage was applied to the gel.  After electrophoresis was completed, gel 
was removed and stained it by soaking in a solution of 0.5µg/ml ethidium bromide for 
30 minutes at room temperature.  Gel was then place on a UV Transilluminator to 
visualize the DNA bands and the size of the DNA fragments were estimated by 
comparison with a 1kb marker.  
       
1.3.3 Extraction of DNA from agarose gel using QIAquick Gel Extraction Kit 
Reagents 
1. Buffer QG 
2. Isopropanol 
3. Buffer PE 
4. 10mM Tris-Cl, pH8.5  
Procedure 
DNA fragment was excised from the agarose gel with a clean, sharp scalpel. Then, the 
gel slice was weighed in a colourless tube. 3 volumes of Buffer QG were added to 1 
volume of gel (100mg ~ 100µL) and incubated at 50°C for 10 minutes (or until the 
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gel slice has completely dissolved). Gel slice was mixed by vortexing the tube every 
2-3 minutes during the incubation to help to dissolve the gel. After the gel slice has 
dissolved completely, colour of the mixture is then checked to ensure it was yellow 
(similar to Buffer QG without dissolved agarose). 1 gel volume of isopropanol was 
added to the sample and mixed.  QIAquick spin column was then placed in a 2ml 
collection tube.  To bind DNA, sample was then applied to the QIAquick column and 
centrifuged for 1 minute. Flow through was discarded and QIAquick column was 
placed back in the same collection tube.  0.75ml of Buffer PE was added to QIAquick 
column and centrifuged for 1 minute.  Flow through was discarded and the QIAquick 
column was centrifuged for an additional 1 minute at 14krpm.  QIAquick column was 
then placed into a clean 1.5ml microcentrifuge tube. 50µL of 10mMTris-Cl, pH8.5 
was added to the center of the QIAquick membrane and column was centrifuged for 1 
minute at maximum speed to elute the DNA. 
 
1.3.4 Restriction endonuclease digestion of DNA 
Reagents 
Nuclease free water   = 15µL 
Restriction enzyme 10X buffer = 2µL 
DNA sample (0.2-1.0µg)  = 2µL 
Restriction enzyme, 2-10U  = 1µL 
Total volume    = 20ul  
Procedure 




1.3.5 DNA ligation 
Reagents 
Vector DNA     = 100ng 
Insert DNA     = 50ng 
T4 DNA Ligase (Weiss units)  = 1µL 
Ligase 10X buffer    = 1µL 
Add nuclease free water to final volume = 10µL 
Procedure 
Ligation reaction was performed at 16°C for overnight incubation. 
 
 
1.3.6 Preparation of bacterial culture and plates 
 
Luria Bertani (LB) medium per liter contained 10g Bacto-tryptone, 5g Bacto-yeast 
extract and 5g NaCl.  The mixture was dissolved in deionized water and pH to 7.5 
with 10N NaOH and autoclaved at 121°C for 15 minutes.   
LB/ antibiotic plate per liter contained 15g of agar added to 1 liter of LB medium and 
autoclaved.  Medium was allowed to cool to 55°C before adding antibiotic to the 
specified final concentration (eg: ampicillin: 100µg/ml).  30-35ml of medium was 
poured into 85mm petri dishes.  Agar was allowed to harden overnight and stored at 
4°C for less than a month. 
 
1.3.7 Competent cells preparation 
Reagents 
75mM CaCl2 solution: 60mM CaCl2 (2H2O), 15% glycerol, 10mM Pipes (HEPES), 




DH5α cells were freshly streaked from glycerol stock onto LB plate and incubated 
overnight at 37°C.  A single colony from LB plate was picked and inoculated in 1ml 
of LB medium.  Culture was incubated overnight at 37°C with shaking 
(approximately 225rpm).  On the following day, the entire overnight night culture was 
inoculated into 100ml of LB medium.  The cells were grown in a 500ml flask until the 
A600 reach 0.4-0.6.  Cell was pelleted down by centrifugation at 3krpm for 5 minutes 
at 4°C.  The cell pellet was gently resuspended in 50ml cold CaCl2 solution and 
incubated on ice for 30 minutes.  Then, the cell was pelleted down by centrifugation 
at 3krpm for 5 minutes at 4°C.  The cell pellet was gently resuspended in 10ml cold 
CaCl2 solution.  The competent cells were aliqouted into pre-chilled sterile eppendorf 
tubes and stored at -80°C.   
 
1.3.8 Heat shock transformation of competent cells 
100µL of competent cells were thawed on ice and 10ng of DNA were added to the 
competent cells and mixed by gently swirling with pipette tip.  Transformation mix 
was incubated on ice for 30 minutes followed by 42°C for 90 seconds incubation.  
Then, the transformation mix was placed on ice to cool for 2 minutes. 3ml of LB 
medium was added and incubated for 45 minutes at 37°C with shaking at ~150rpm.  
100-200µL of the transformation mix was then plated onto selection plates and 






1.3.9 Plasmid DNA minipreps (According to Miniprep protocol from Promega, 
USA) 
Reagents 
1. Cell resuspension solution (50mM Tris-HCl, pH7.5, 10mM EDTA, 100ug/ml 
RNase A) 
2. Cell lysis solution ( 0.2N NaOH, 1% SDS) 
3. Cell neutralizing solution (1.32M potassium acetate, pH 4.8) 
4. Column wash solution (190mM potassium acetate, 20mM Tris-HCl, pH7.5, 
1mM EDTA, 55% ethanol) 
5. Nuclease free water 
Procedure 
Single bacteria colony was inoculated into 5ml of LB medium containing the 
appropriate antibiotic.  Culture was incubated overnight at 37°C with vigorous 
shaking for 12-16 hours. 1.5ml of the overnight culture was placed into a 
microcentrifuge tube and centrifuged at 14krpm for 1 minute.  Medium was removed 
by aspiration and the pellet was resuspended by vortexing in 250µL of cell 
resuspension solution.  250µL of cell lysis solution was then added and mixed by 
inversion. Then, 350µL of Wizard plus SV Neutralizing Solution was added to 
neutralize the cell lysate.  The cell lysate was mixed by inversion and centrifuge at 
14krpm for 10 minutes.  Clear supernatant was transferred to the prepared Spin 
Column without disturbing or transferring any of the white precipitate with the 
supernatant.  The spin Column was centrifuged at 14krpm for 1 minute.  Then, the 
Spin Column was removed from the tube and flow through was discarded from the 
collection tube.  The spin Column was reinserted into the Collection Tube and 750µL 
of Column Wash Solution was added to the Spin Column.  The spin column was then 
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centrifuged at 14krpm for 1 minute.  Following that, the Spin Column was removed 
from the tube and flow through was discarded from the collection tube.  The washing 
procedure was repeated using 250µL of Column Wash Solution and centrifuged at 
14krpm for 2 minutes.  The spin Column was transferred to a new, sterile 1.5ml 
microcentrifuge tube.  Plasmid DNA was eluted by adding 100µL of Nuclease-Free 
Water to the Spin Column and centrifuged at 14krpm for 1 minute.  After DNA was 
eluted, the Spin Column was discarded and purified DNA was stored at -20°C. 
 
1.3.10 DNA Sequencing 
Reagents 
 
ABI Prism Sequencing dye Version 3  = 4µL 
5X sequencing buffer    = 2µL 
Primer      = 2-3 pmol 
Plasmid     = 200-500ng 
Add sterile water to total volume  = 20µL 
Procedure 
The sequencing of a cloned DNA was performed according to the reagents stated 
above and the sequencing reaction was carried out at the following setting: 
1.96°C- 30 seconds 
2.50°C- 15 seconds 
3.60°C- 4 minutes 
repeat step 1 to step 3 for 25 cycles 
4.4°C 
 
After the completion of sequencing reaction, 14.5µL of sterile water, 3µL of 3M 
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sodium acetate, pH 5.0 and 62.5µL of 95% ethanol were added to the reaction tube.  
The tube was vortex and sat on ice for 10 minutes, then spun at 14krpm for 20 
minutes.  Solution was removed and pellet was washed with 250µL of 70% ethanol 
and centrifuge at 14krpm for 10 minutes.  Ethanol was decanted and pellet was 
allowed to air dry before analysis using the ABI Prism 377 DNA sequencer at the 
National University of Singapore Medical Institutes DNA sequencing facility. 
 
1.3.11 Midiprep (According to Midiprep protocol from Qiagen, Germany) 
Reagents 
1. Buffer P1 
2. Buffer P2 
3. Buffer P3 
4. Buffer QBT 
5. Buffer QC 
6. Isopropanol 
7. Buffer QF 
8. 70% ethanol 
9. TE, pH8.0 (10mM Tris-HCL, pH8.0, 1mM EDTA)  
Procedure 
 A single colony was picked from a freshly streaked selective plate and inoculated in a 
2ml LB medium containing the appropriate selective antibiotic.  Culture was 
incubated overnight at 37°C with vigorous shaking ~ 300rpm.  1ml of the overnight 
culture was added in 100ml medium and grown at 37°C for 12-16 hours with vigorous 
shaking.  Bacterial cells were harvested by centrifugation at 6k x g for 15 minutes at 
4°C.  Bacterial pellet was resuspended in 4ml of Buffer P1 followed by 4ml of Buffer 
 25
P2.  Bacterial lysate was gently mixed by inverting the tube 4-6 times and incubated 
at room temperature for 5 minutes.  10ml of chilled Buffer P3 was added to the lysate, 
mixed immediately by gently inverting the tube 4 to 6 times and incubated on ice for 
15 minutes.  Cell lysate was then centrifuged at ≥ 20k x g for 30 minutes at 4°C.  
Meanwhile, QIAGEN-tip 100 was equilibrated by applying 4ml of Buffer QBT unto 
the column and was allowed to empty by gravity flow.  After centrifugation was 
completed, supernatant containing plasmid DNA was removed and applied to 
QIAGEN-tip and allowed to enter the resin by gravity flow.  QIAGEN-tip was 
washed with 2X10ml of Buffer QC.  DNA was eluted with 5ml of Buffer QF and was 
precipitated by adding 3.5ml of room temperature isopropanol to the eluted DNA.  
The mixture was subjected to centrifugation immediately at ≥15k x g for 30 minutes 
at 4°C.  DNA pellet was then washed with 2ml of room temperature 70% ethanol and 
centrifuged at 15k x g for 10 minutes.  Pellet was air dried for 5-10 minutes and DNA 
was dissolved in TE, pH8.0.   
 
1.3.12 Cell culture medium 
CHO cells were cultured in RPMI 1640 medium (Sigma, MO) containing 10% fetal 
bovine serum (FBS) and appropriate supplements of L-glutamine, penicillin and 
streptomycin (Life Technologies, USA). 
 
1.3.13 Preparation of G418 solution 
50mg/ml of G418 stock was prepared by dissolving the powder form of G418 with 








1. Lipofectamine (Invitrogen, USA) 
 
2. Opti-MEM 1 (Invitrogen, USA) 
 
3. RPMI complete medium 
4. Typsin-EDTA (Invitrogen, USA) 
5. 50mg/ml G418 (Calbiochem, USA) 
Procedure 
In a 6 wells plate, ~ 1.3 x 105 CHO cells were seeded per well in a 2ml of the RPMI 
complete medium.  Cells were incubated at 37°C in a CO2 incubator until the cells 
were 50-80% confluent.  The following solutions were prepared in 12 X 75mm sterile 
tubes: Solution A: For each transfection, 1µg of DNA was diluted into 100µL Opti-
MEM 1 serum free medium.  Solution B: For each transfection, 3µL of Lipofectamine 
was diluted into 100µL Opti-MEM 1 serum free medium.  The two solutions were 
combined, gently mixed and incubated at room temperature for 45 minutes to allow 
DNA-liposome complexes to form.  The cells were rinsed once with 2ml of serum-
free medium.  For each transfection, 0.8ml of serum free medium was added to the 
tube containing the complexes.  The mixture was gently mixed and the diluted 
complex solution was overlaid onto the rinsed cells.  Cells were incubated with the 
complexes for 7 hours at 37°C in a CO2 incubator then changed to RPMI complete 
medium.  Cells were incubated for 48 hours at 37°C in a CO2 incubator before 
medium was changed into RPMI complete medium containing 0.4mg/ml G418 for 
selection.  RPMI complete medium containing 0.4mg/ml G418 was changed once 
every 2-3 days of incubation.  Selection was carrying out up to 2 weeks until a single 
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colony could be observed from the well.  Single colony was picked from the 6 wells 
plate by using 3-4µL of trypsin.  Colony was transferred into 96 wells plate and 
incubated with RPMI complete medium containing 0.2mg/ml of G418.  Colony was 
cultured till it reached confluence; it was sub-cultured into 24 wells plate and then to 
6 wells plate.  Expressions of recombinant human CD157-Fc fusion protein from 
different clones were then determined by Western blotting and ADP-ribosyl cyclase 
assay.  The clone that gave the highest expression was then kept as stock. 
 
1.3.15 Purification of recombinant human CD157-Fc protein using anti-human 
IgG (Fc specific) Agarose 
Reagents 
1. 1XPBS 
2. 0.1M Glycine, pH 3.0 
3. 1M Tris-HCI, pH 8.0 
Materials  
1. Anti-human IgG agarose (Sigma, USA) 
2. Dialysis tubing (Sigma, USA) 
3. Centriprep 30 ( Amicon, USA) 
Procedure 
Secreted recombinant human CD157-Fc fusion protein was collected from the cell 
culture medium, concentrated using Centriprep 30 and subjected to dialysis against 
1XPBS.  Dialyzed fusion protein was then allowed to bind with anti-human IgG 
agarose for 3 hours at 4°C on a rocker.  Suspension mix was then poured into a small 
column and washed several times with 1XPBS.  Recombinant protein was then eluted 
using 0.1M Glycine at pH 3.0 and the eluate was neutralized with 1/10 volume of 1M 
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Tris-HCl, pH 8.0.  
 
1.3.16 SDS-PAGE (Tris-glycine system) 
Reagents 
1. 30% Bis/Acrylamide solution 
2. 1.5M Tris-Cl, pH8.8 
3. 1M Tris-CI, pH6.8 
4.10% SDS 
5. 10% ammonium persulfate 
6. TEMED 
7. Tris-Glycine running buffer: 25mM Tris, 250mM Glycine, pH8.3 and 0.1% SDS. 
8. 6X Laemmli sample buffer: 0.35M Tris-HCI (pH6.8), 10.28% (w/v) SDS and 36% 
(v/v) glycerol, 5% β-mercaptoethanol and 0.012% (w/v) bromophenol blue. 
9. Prestained protein marker 
Procedure 
12% of resolving gel and 5% of stacking gel were prepared by adding the reagents as 
follows: 
Components for gel mix 12% resolving gel 5% stacking gel 
Water 3.3ml 4.1ml 
30% Bis/Acrylamide 4.0ml 1.0ml 
1.5M Tris-Cl, pH8.8 2.5ml  
1M Tris-Cl, pH 6.8  0.75ml 
10% SDS 0.1ml 0.06ml 
10% ammonium persulfate 0.1ml 0.06ml 
TEMED 0.004ml 0.004ml 
Total volume 10ml 6ml 
 
After adding TEMED to the resolving gel, the resolving gel mixture was poured into a 
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mini-gel casting chamber with a spacer placed in between the glass plates.  A length 
of few centimeters at the top was left empty for loading the stacking gel.  After the 
resolving gel had polymerized, TEMED was then added to the stacking gel and 
poured on top of the resolving gel.  A comb was inserted into the stacking gel and 
allowed it to be polymerized.  After the stacking gel had polymerized, the comb was 
removed and the mini-gel caster was placed into the electrophoresis tank containing 
Tris-Glycine running buffer. 
 
Electrophoresis of protein samples 
1x Laemmli sample buffer was added to protein samples and boiled for 5 minutes 
before loading into SDS-PAGE gel.  Protein marker was loaded into one of the well.  
The SDS-PAGE gel was electrophoresed at 100-200V. 
 
1.3.17 Coomassie blue staining 
Reagents 
1. Coomassie blue staining solution: 0.1% coomassie brilliant blue R-250, 30% 
absolute ethanol, 10% glacial acetic acid. 
2. Destaining solution: 30% absolute ethanol, 8% glacial acetic acid. 
Procedure 
SDS-PAGE gel was placed in the staining solution immediately after electrophoresis.  
Gel was stained at room temperature with gentle agitation for at least 30 minutes.  
After staining, the staining solution was poured off and destaining solution was added 
and agitated gently at room temperature.  Destaining solutions was changed with fresh 
destaining solutions until the background was cleared. 
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1.3.18 Western blotting 
Reagents 
1. Transfer buffer: 25mM Tris-HCl (pH8.3), 192mM Glycine and 20% 
Methanol. 
2. TBST: 100mM Tris, 300mM NaCl, pH to 7.5 before adding 0.1% Tween 20 
3. TBS: 100mM Tris, 300mM NaCl, pH to 7.5 
4. 10% casein 
5. Primary and secondary antibody 
6. ECL detection reagents (Amersham Biosciences, UK)  
Procedure 
Protein samples were subjected to electrophoresis in SDS-PAGE and transferred onto 
nitrocellulose membrane.  The membrane was blocked in 1% casein prepared in TBS 
for 1 hour on a rocker.  After blocking, the membrane was washed 3 times for 5 
minutes each with TBST.  Then, the membrane was incubated with primary antibody 
in appropriate dilution in 0.5% casein/TBS for 1 hour at room temperature on a 
rocker.  After the membrane was washed 3 times for 5 minutes each with TBST, it 
was incubated with HRP-conjugated secondary antibody in an appropriate dilution in 
0.5% casein/TBS for 1 hour at room temperature on a rocker.  Then, the membrane 
was washed 3 times for 5 minutes each with TBST again.  Finally, the immuno-







1.3.19 ADP- ribosyl cyclase assay  
Reagents 
1. Purified protein of CD157-Fc 
2. 1.0mM NGD+ 
3. 1.0M ZnCl2 
4. 50mM MES, pH6.0 
Procedure 
ADP-ribose cyclase assay was performed in a 200ul reaction containing 100uM 
NGD+, 50mM MES (pH6.0), 10ug/ml purified proteins of CD157-Fc and 10mM 
ZnCI2 at 37°C.  The fluorescence of cGDPR was read at 410nM after excitation at 
300nM in a luminescence spectrometer (Perkin Elmer, USA).  A negative control was 
performed by using purified proteins inactivated by boiling for 10 minutes in the 














1.4 Results and Discussions 
1.4.1 Construction of CD157-Fc fusion protein 
CD157 which functions as a surface receptor plays a role in signal 
transduction pathway as described by other researchers. However, detailed 
information regarding how the receptor initiates the downstream signaling is yet to be 
reported.  Therefore, no interacting partner(s) for CD157 has been discovered.  In 
order to screen for interacting protein(s) of CD157, a soluble CD157 protein with Fc 
tag was designed to ease the purification and detection procedure.  The schematic 
diagram of construction of recombinant CD157-Fc fusion protein is shown in Figure 
1.1.  
The cDNA encoding soluble human CD157 fragment was amplified from 
human CD157 cDNA template in vector PXJ41 using primers SHUCD157 and 
ASHUCD157 (refer to material 1.2.1).  PCR was carried out at the annealing 
temperature of 52°C according to method 1.3.1 and the PCR product was run on 
agarose gel as described in method 1.3.2. The result showed DNA fragment at size ~ 
900bp in Figure 1.2.  The Fc fragment was amplified from ESD1 heavy chain cDNA 
cloned in vector pSPORT1 using primers SHUFC and ASHUFC (refer to material 
1.2.1) and the PCR was carried out at the annealing temperature of 67°C according to 
method 1.3.1.  The result showed the DNA fragment at size ~ 700bp in Figure 1.3.  
Amplified fragments of CD157 and Fc were purified using QIAquick gel extraction 
kit as described in method 1.3.3 before carried out the fusion PCR.  The ectodomain 
minus the GPI-anchoring sequence of human CD157 was used to fuse to the hinge, 
CH2 and CH3 regions of human IgG1 via a bridging sequence (glycine-proline-
glycine), which functions as a spacer.  Primers SHUCD157 and ASHUFC were used 
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to generate such fusion (refer to material 1.2.1).  The PCR was carried out at 
annealing temperature of 58°C according to method 1.3.1 and produced DNA 
fragment size of ~1.6kb (see Figure 1.4).  The 1.6kb fragment of PCR product was 
purified and subsequently subjected to restriction enzyme digestion (method 1.3.4) 
using KpnI and EcoRI before sub-cloning.  pGEMT vector, used for cloning was also 
digested with the same set of restriction enzymes.  Digested fragments were then 
purified and ready for sub-cloning by adding vector and insert in ligation reaction as 
described in method 1.3.5.  Ligation mixture was then transformed into DH5α 
competent cell (method 1.3.8) and plated onto ampicillin plate.  The antibiotic 
selection plates were prepared accordingly to method 1.3.6, and the competent cells 
used for the transformation were prepared according to the method 1.3.7.  After 
overnight incubation, colonies were observed on the antibiotic selection plate.  
Putative clones were picked for plasmid miniprep (method 1.3.9) and the positive 
clones were verified by PCR, restriction digestion and DNA sequencing (method 
1.3.10) (data not shown).  In order to express the recombinant protein in the 
mammalian cell, the CD157-Fc fusion gene was sub-cloned into PXJ41 expression 
vector.  Positive clones that were successfully cloned into PXJ41 were verified by 
restriction digest and DNA sequencing.  Sequencing results showed that the CD157-
Fc gene was cloned in the correct reading frame into PXJ41 (data not shown).  Large 
scale plasmid purification (Midiprep) was carried out as described in method 1.3.11 to 














Figure 1.1: Schematic diagram of the construction of CD157-Fc fusion protein. 
Specific primers were used to amplify CD157 without GPI site from the human cDNA 
and Fc region from human IgG.  CD157 and Fc fragment were joined at bridging 





















Figure 1.2: Electrophoresis of PCR 
product of CD157 fragment without GPI 
sequence on 1% agarose gel.   
PCR was carried out using SHUCD157 and 
ASHUCD157 specific primers from human 
CD157 cDNA in vector PXJ41. 
700bp 
Figure 1.3: Electrophoresis of PCR 
product of Fc fragment on 1% agarose gel. 
PCR was carried out using SHUFC and 
ASHUFC specific primers from ESD1 heavy 
chain cDNA in vector pSPORT1. 
1.6kb
Figure 1.4: Electrophoresis of PCR product 
of CD157-Fc on 1% agarose gel.   
PCR was carried out using SHUCD157 and 
ASHUFC specific primers from purified 
fragments of CD157 and Fc. 
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1.4.2 Expression of CD157-Fc fusion protein in CHO cell lines 
 It was noted that protein expression from transient transfection in mammalian 
system could not give high yield of protein.  Therefore, in order to harvest large 
amount of proteins and obtained homogenous expression, stable transfection in CHO 
cell line has been performed according to method 1.3.14.  Furthermore, by having the 
stable transfected cell lines, the protein could be expressed constitutively.  CD157-Fc 
fusion protein which is soluble would be secreted in the culture medium; hence, 
culture medium could be collected and purified by affinity purification using anti-
human IgG (Fc specific) agarose beads (method 1.3.15).  Purified protein was run in a 
12% SDS-PAGE gel in method 1.3.16 and subjected to Coomassie staining (method 
1.3.17) and Western blotting detection (method 1.3.18).  Protein concentration of 
CD157-Fc fusion protein was estimated by running a standard of bovine serum 
albumin (BSA) in different concentration with the purified protein on a SDS-PAGE 
followed by staining the gel with Coomassie dye.  Coomassie staining showed that the 
purified product of recombinant CD157-Fc (~ 75kDa) has a concentration of ~ 
50µg/ml (Figure 1.5) with a yield of 50mg/l.  CD157-Fc fusion protein was further 
characterized by immunoblotting.  In Figure 1.6, Western blotting result showed a 
~75kDa band in the eluted fractions of CD157-Fc fusion protein when the 
nitrocellulose membrane was probed with anti-Fc peroxidase conjugated antibody 
(Sigma, USA).  The molecular size of CD157-Fc fusion protein as shown in 
Coomassie stain and Western blot were higher than the expected deduced size of 
~59kDa.  This suggests the fusion protein has undergone glycosylation process.  In 
fact, there are four potential N-glycosylation sites in CD157 as predicted from its 
amino acid sequence (Itoh et al., 1994 and Dong et al., 1994).  It was reported that 
CHO expressed recombinant human CD157 at a higher molecular size (Kaisho et al., 
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1994), and this finding was consistent with our findings where CHO was used to 
express recombinant human CD157-Fc fusion protein.   
ADP-ribosyl cyclase assay, as described in method 1.3.19, was carried out to 
test the functionality of the recombinant CD157-Fc fusion protein.  As shown in 
Figure 1.7, CD157-Fc fusion protein exhibited cyclase activity when 100µM of NGD+ 
substrate was added in the reaction mix. Lower cyclase activity was observed when 
ZnCl2 was omitted in the assay.  This demonstrates that ZnCl2 acts as a cofactor in the 
cyclase activity assay.  However, no activity was observed when the recombinant 
protein was inactivated by boiling for 10 minutes in the presence of 100mM β-
mecaptoethanol.  Therefore, it is concluded that the recombinant fusion protein 
(CD157-Fc) produced from CHO was functional and could be used for subsequent 








































Figure 1.5: Expression of CD157-Fc fusion protein.   
Cultured medium of stable transfected CHO/CD157-Fc cell was collected and 
pass through affinity purification column which packed with anti-human Fc 
agarose beads.  Purified CD157-Fc protein was subjected to 12% SDS-PAGE 
and stained with Coomassie blue.  
75 kDa 
Figure 1.6: Western blot of recombinant fusion protein CD157-Fc.   
Mock and various fractions (F1 till F7) of eluted purified CD157-Fc fusion 
protein from the affinity column was analyzed on the Western blot and 
probed with anti-Fc peroxidase conjugated antibody.  The expression of 
CD157-Fc fusion protein (75kDa) was indicated by plus (+) and (-) minus 
signs. 
75 kDa
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Well H3 H4 H5
Slope 108.40 8031.9 1412.6
Figure 1.7: ADP-ribosyl cyclase activity of recombinant fusion protein 
CD157-Fc.  
ADP-ribosyl cyclase activity of CD157- Fc protein (10ug/ml) was determined 
using 50mM MES (pH 6.0), with or without 10mM ZnCl2 (indicated by + or –
sign) and 100µM NGD+ as the substrate.  Activity was read at 410nM after 
excitation at 300nM in a luminescence spectrometer. A negative control was 
assayed by using purified protein inactivated by boiling for 10 minutes in the 




















Identification of CD157 interacting partner(s) using yeast 



































The yeast two-hybrid system is an in vivo assay designed to detect protein-
protein interactions in their native conformation (Chien et al., 1991).  In general, in 
any two-hybrid experiment a protein of interest (X) is fused to a DNA –binding 
domain (BD) and transformed in a yeast host cell bearing a reporter gene controlling 
this DNA-binding domain. When this fusion protein cannot activate transcription on 
its own, it can be used as “bait” or as a “target” to screen a library of cDNA clones (Y) 
that are fused to a transcriptional activation domain (AD). The cDNA clones within 
the library that encode proteins capable of forming protein-protein interactions with 
the bait are identified by virtue of their ability to cause activation of the reporter gene.  
The detection of the activity of the transcriptional factor via selection of the reporter 
gene expression is the basis for the identification of the interacting proteins.  The 
































































Figure 2.1: Outline of the two-hybrid system 
a) A hybrid protein is generated that includes a DNA-binding 
domain and a protein X.  This hybrid can bind to DNA but 
will not activate transcription if X does not have an activation 
domain. 
b) Another hybrid protein is generated that fused an activation 
domain to a protein Y.  This hybrid protein will not activate 
transcription because it does not bind to upstream activation 
sequence (UAS). 
c) Both hybrid proteins are produced in the same transformant. 
The X and Y proteins bind noncovalently and activate 






The yeast-two hybrid approach has been employed to identify the interacting 
proteins for CD157.  CD157-GPI (full length) and CD157 (without GPI) which fused 
with DNA-binding domain (BD) was constructed respectively to act as bait in this 
experiment.  These baits were used to screen against either HeLa or B cell cDNA 
library that fused to transcriptional activation domain (AD).  After several rounds of 
screening via selection of the reporter gene expression, seven putative candidates 
arising from HeLa cDNA using CD157-GPI as bait were identified.   
They are: 
1. Homo sapiens, similar to DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 
36 
2. Homo sapiens, calcium-regulated heat stable protein 
3. Homo sapiens, proteasome (prosome, macropain) subunit, alpha type, 2 
4. Homo sapiens, GPI-anchored metastasis-associated protein homolog (C4.4A) 
5. Homo sapiens, NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 
6. Homo sapiens, heat shock 10kDa protein 1 (chaperonin 10) 
7. Homo sapiens, fuse-binding protein-interacting repressor (SIAHBP1), 










2.2.1 Oligonucleotides Synthesis 
All oligonucleotides were synthesized from PROLIGO Primers & Probes 
S-Cub CD157  5’ gccgaattcaaaaaaatggcggcccaggggtgc 3’ 
Yeast R  5’ gccgccaagcttattctgtataaagacttgggg 3’ 
AS-Cub CD157 5’ gccctcgagagttgagtccgggaagc 3’ 
 
2.2.2 Yeast strains 
Name Genotype Reference 
NLY21 MATa ura3-52, his3 200, leu2-1, trp1 63, lys2-358, 
gal4, gal80 
Zaman et al., 2001 
HF7c MATa ura3-52,trp1-901 leu2-3,112, his3-200 ade2-








Name Domain Selective 
markers 
Reference 
pHAY1 GAL4-BD TRP1 Derived from pY1 vector (Sadowski et 
al., 1992), constructed by Dr.Lehming, 
where it carries HA tag.  
pACT GAL4-AD LEU2, AmpR Durfee et al., 1993 
Y1GAL4  TRP1 Sadowski et al., 1992 
pADNS  LEU2, AmpR Colicelli et al., 1989 
 
2.2.4 cDNA library 
Hela cDNA library and B cell cDNA library which fused to pACT-AD were obtained 
from Clontech, USA. 
 
2.2.5 Competent cell 
DH10B:F-mcrA ∆(mrr-hsdRMS-mcrBC) Φ80dlacZ∆M15 ∆lacX74 deoR recA1 endA1 
araD139∆(ara. leu)7697 galU galK λ- rpsL nupG 
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2.2.6 X-Gal 
 X-Gal was dissolved in dimethyformamide to make 40mg/ml stock solution.  Tube 
was wrapped in aluminium foil to prevent damage by light and stored at –20°C. 
 
2.2.7 Medium 
1. YPD: 1% Bacto yeast extract, 2% Bacto-peptone, 2% dextrose 
2. YPAD: 1% Bacto yeast extract, 2% Bacto-peptone, 2% dextrose, 0.003% adenine 
3. Synthetic dropout (SD) medium: 
a. WL: 0.07% Amino acid supplements lacking trytophan (W) and leucine (L), 
0.7% yeast nitrogen base without amino acid, 2% glucose (D+) anhydrous. 
b. WLH: 0.07% Amino acid supplements lacking trytophan (W), leucine (L) and 
histidine (H), 0.7% yeast nitrogen base without amino acid, 2% glucose (D+) 
anhydrous. 
c. WUL: 0.07% Amino acid supplements lacking trytophan (W), leucine (L) and 




1. YPD agar: 1% Bacto yeast extract, 2% Bacto-peptone, 2% Dextrose, 2% Bacto-
agar 
2. Synthetic dropout (SD) plate: 
a. WL agar: 0.07% Amino acid supplements lacking trytophan (W) and leucine 
(L), 0.7% yeast nitrogen base without amino acid, 2% glucose (D+) anhydrous, 
1.5% Bacto-agar. 
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b. WLH agar: 0.07% Amino acid supplements lacking trytophan (W) and leucine 
(L), 0.7% yeast nitrogen base without amino acid, 2% glucose (D+) anhydrous, 
1.5% Bacto-agar. 
c. WUL agar: 0.07% Amino acid supplements lacking trytophan (W), leucine (L) 
and uracil (U), 0.7% yeast nitrogen base without amino acid, 2% glucose (D+) 
anhydrous, 1.5% Bacto-agar. 
3. X-Gal plate: 60mM Na2HPO4, 40mM NaH2PO4, pH 7.0, 15g Bacto agar per liter.  
Top up with 1 liter water and autoclave.  Medium was allowed to cool down before 
adding 40mg/l of X-Gal. 
 
2.2.9 Electroporator 
MicroPulser Electroporator was purchased from BioRad, USA. 
 
2.3 Methods 
2.3.1 Preparation of yeast competent cell 
Reagents 
1. YPAD medium 
2. 0.1M lithium acetate in 1mM TE, pH7.5 
Procedure 
Single colony was inoculated into YPAD medium and allowed to grow till A600 ~ 0.6 
at 30°C.  Cell was spun down by centrifugation at 4krpm for 5 minutes.  Cell pellet 
was resuspended in 1ml sterile water and spun down by centrifugation at 7krpm for 1 
minute.  The cell pellet was then resuspended in 500µL of 0.1M lithium acetate in 
1mM TE pH 7.5.  It was then incubated at 30°C for 1 hour.  Cells are competently 
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made and are ready to be used for transformation or could be stored at 4°C up to 2 
weeks.  
 
2.3.2 Yeast transformation 
Reagents 
1. Herring testis carrier DNA 
2. Yeast competent cell 
3. 40% PEG Lithium Acetate/ TE: 40% PEG, 0.1M Lithium Acetate, pH 7.5, 1X TE, 
pH 7.5. 
Procedure 
3µL herring sperm was added to 1µL of plasmid.  10µL of competent cells was then 
added to the mixture above followed by addition of 100µL of 40% PEG Lithium 
Acetate/TE.  It was mixed and incubated at 30°C for 45 minutes.  Then, the 
transformation mix was subjected to heat shock at 42°C for 15 minutes.  It was then 
spun down at 7krpm for 1 minute and the supernatant containing 40% PEG Lithium 
Acetate was then removed.  Transformant was then re-suspended in 50µL sterile 
water and spread onto selective plate. 
 
2.3.3 Yeast plasmid isolation 
Reagents 
1. Yeast breaking buffer: 2%(v/v) Triton X-100, 1% (v/v) SDS, 100mM NaCI, 
10mM Tris-CI, pH 8.0, 1mM EDTA, pH 8.0. 
2. Phenol: Chloroform 5:1 ratio 




Single colony was inoculated into selective medium and grow overnight at 30°C.  Cell 
was spun down by centrifugation at 4krpm for 5 minutes.  Then, 200µL of breaking 
buffer was added to resuspend the pellet and subjected it for vortexing.  425-600µM 
diameter of glass beads and 200µL of 5:1 ratio of phenol chloroform was added into 
the suspension and vortex vigorously for 5 minutes.  200µL sterile water was then 
added to the suspension and centrifuge at 14krpm for 5 minutes.  Supernatant was 
transferred to a fresh tube and 1ml of absolute ethanol was added, mixed and 
centrifuged at 14krpm for 10 minutes.  Pellet was washed with 1 ml of 70% ethanol 
and followed by centrifugation at 14krpm for 5 minutes.  Supernatant was discarded 
and pellet (purified plasmid) was allowed to air dry.  Finally, plasmid was dissolved 
in sterile water and kept at -20°C. 
 
2.3.4 Bacterial electro competent cell preparation 
Reagents 
Ice cold water, LB medium, Ice-cold 10% glycerol 
Procedure 
Single colony of DH10B was inoculated into 5ml of LB medium and allowed to grow 
overnight at 37°C with moderate shaking ~ 300rpm.  2.5ml of the overnight culture 
was inoculated into 500ml of LB medium, culture at 37°C with shaking at 300rpm 
until A600 reaches ~ 0.5.  Cells were then chilled on ice for 15 minutes and transferred 
to a pre-chilled centrifuge bottle.  Cells were centrifuged at 4.2krpm for 20 minutes.  
Supernatant was discarded immediately and pellet was re-suspended in 500ml of ice-
cold water.  Cells were centrifuged at 4200rpm for 20 minutes and the supernatant 
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was discarded immediately.  Pellet was resuspended in 40ml of ice-cold 10% glycerol 
and ready to be used for electroporation. 
 
2.3.5 Electroporation transformation method 
A 50µl of DH10B cell was thawed on ice and 1µl of plasmid was added.  The content 
was mixed by tapping the tube gently and was incubated on ice for 1 minute.  The 
content was transferred into a chilled electroporation cuvette and placed in an 
electroporation chamber.  Single pulse of 1.5kV at 25µF was applied using a 
MicroPulser Electroporator (Bio-Rad, USA).  1ml of LB medium was added to the 
cuvette and transferred to a culture tube and incubated at 37°C for 1 hour with 
shaking ~200rpm.  100-200µL of the transformation mix was then plated onto 
selection plates and incubated overnight at 37°C. 
 
2.3.6 Colony-lift filter assay 
Material 
1. Nitrocellulose membrane 
2. Forceps 
3. Liquid nitrogen 
4. X-Gal plate 
Procedure 
Using a forcep, nitrocellulose membrane was placed over the surface of the plate of 
colonies to be assayed.  The membrane was carefully lifted off the agar plate with 
forcep and transferred to a pool of liquid nitrogen.  The membrane was submerged 
completely for 10 seconds.  After the membrane has frozen completely, it was 
removed from the liquid nitrogen and allowed to thaw at room temperature.  This 
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freeze/ thaw treatment permeabilizes the cells.  The membrane was then placed 
carefully with the colony side up on the X-Gal plate; avoid trapping air bubbles in 
between the membrane and plate.  Plate was incubated at 30°C (or room temperature) 
and checked periodically for the appearance of blue colonies.     
 
2.3.7 Serial dilution assay 
Procedure 
A serial dilution of sample up to 10-6 was performed in a 96 well plate.  90µL of 
sterile water was pipetted into 6 well horizontally.  A clump of yeast cell colony was 
picked using pipette tip and resuspended into the first well.  Then, 10µL from the first 
well was transferred into the second well.  The process was repeated for the rest of the 
well till 10-6.  5µL of each dilution was plated onto selective plate and incubated at 
























2.4 Results and discussion 
2.4.1 Construction and characterization of the bait protein 
CD157 with either GPI anchorage (CD157-GPI) (AA1-318) or GPI free 
(CD157) (AA1-299) was used as bait to fuse with DNA-BD (pHAY1).  These two 
baits (CD157-GPI-pHAY1 and CD157-pHAY1) were constructed in order to 
determine whether GPI anchorage region or CD157 region itself play a part in search 
of the interaction partner.  Primers S-Cub CD157 and Yeast R (refer to material 2.2.1) 
were used to amplify CD157 without GPI site, whereas primers S-Cub CD157 and 
AS-Cub CD157 (refer to material 2.2.1) were used to amplify full length CD157-GPI 
fragment.  PCR were carried out at annealing temperature of 60ºC according to 
method 1.3.1.  PCR fragment of CD157-GPI and CD157 at ~1kb (Figure 2.2) was 
amplified and purified according to method 1.3.3.  Both purified CD157 and CD157-
GPI fragment were subjected to restriction digestion.  For CD157 fragment, it was 
digested by enzymes EcoRI and HindIII, and CD157-GPI fragment was digested 
using EcoRI and XhoI according to method 1.3.4.  pHAY1 vector which is a DNA-
BD vector was used as a cloning vector for the bait construction. pHAY1 at multiple 
cloning sites after GAL4 (1-147) was digested either by EcoRI and HindIII or EcoRI 
and SalI to clone the CD157 and CD157-GPI fragment respectively.  pHAY1 vector 
which does not posses the XhoI digestion site to clone the CD157-GPI fragment, was 
digested by SalI enzyme instead.  This method could generate a compatible cloning 
site for XhoI, however its recognition site for SalI will be disrupted.  The schematic 





















Figure 2.2: Electrophoresis of PCR product of CD157 and CD157-GPI
on 1% agarose gel.   
Lane 1 :  PCR product of CD157using S-Cub and Yeast R primes.  
Lane 2 : PCR product of CD157-GPI using S-Cub CD157 and AS-Cub 
CD157 primers. 
   1              2
Figure 2.3: Schematic diagram of bait construction approach. 
Left panel showed the construction of CD157-pHAY1. 
















After purifying the digested construct of vector and PCR fragment (Figure 2.4), 
ligation was carried out according to method 1.3.5.  Subsequently transformation was 
performed in DH5α according to method 1.3.8.  Several colonies were picked from 
the successful transformation for plasmid isolations.  Positive clones were verified by 
restriction digest and sequencing to ensure the insert (CD157 or CD157-GPI) was 
cloned in-frame in the pHAY1 vector (data not shown).   
The correct bait construct of CD157-pHAY1 and CD157-GPI-pHAY1 was 
tested for autonomous reporter gene expression without the presence of Gal4 
activation domain (AD).  Plasmid of the bait construct (CD157-pHAY1 or CD157-
GPI-pHAY1), positive control (Y1Gal4) and negative control (pHAY1) were 
transformed into yeast competent cell according to method 2.3.2 and plated onto 
Digested fragment of 
pHAY1 vector (6.7kb) 
Figure 2.4: Electrophoresis of restriction digested product of pHAY1 and CD157/ 
CD157-GPI on 1% agarose gel. 
Lane 1: CD157 fragment was digested with EcoRI and HindIII 
Lane 2: CD157-GPI fragment was digested with EcoRI and XhoI 
Lane 3: pHAY1 was digested with EcoRI and HindIII to clone CD157 fragment 
Lane 4: pHAY1 was digested with EcoRI and SalI to clone CD157-GPI fragment 
Digested fragments of 
CD157/ CD157-GPI 
(~ 1kb) 
1 2 3 4
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selection synthetic dropout plate.  The transformations were incubated for 3 days at 
30°C.   
Synthetic dropout (SD) medium is used to test for genes involved in specific 
biosynthetic pathways and to select for gene function in transformation experiments.  
Dropout powder lacks one or more nutrients but contains all other nutrients.  Two 
different yeast strains were used in this study, NLY21 and HF7c, in order to observe 
the reporter gene expression regulation.  The reporter gene for NLY21 and HF7c is 
URA3 and HIS3, respectively.  HF7c has the “tight” regulation of the expression level 
in the absence of induction, but achieve high expression when induction of a positive 
two-hybrid interaction occurred. Table 2.1 showed the different bait constructs that 
were used to transform into yeast strains.   
 
Bait construct Yeast strain 
CD157GPI-pHAY1 HF7c NLY21 
CD157-pHAY1 Hf7c NLY21 
 
Table 2.1: Two different bait constructs (CD157GPI-pHAY1 or CD157-pHAY1) 
were transformed into either HF7c or NLY21 yeast strain. 
 
For transformation performed on HF7c yeast competent cell, cells were plated 
onto –Trp (W), -Trp/-His (WH) dropout medium plates. Whereas for transformation 
performed on NLY21 yeast competent cell, cells were plated onto -Trp (W), -Trp/-
Ura (WU) dropout medium plate.  If the bait construct has the intrinsic reporter gene 
expression, it could drive the expression of either HIS or URA3 in HF7c and NLY21, 
respectively.  Therefore, the transformation could survive either in –Trp/-His (WH) or 
–TRP/-Ura (WU) plates.   
After 3 days of incubation, it was observed that only positive control plasmid 
(Y1Gal4) transformed in either HF7c or NLY21 grew on –Trp/-His (WH) and –Trp/-
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Ura (WU) plates (see Figure 2.5).  Negative control and the bait constructs survived 
only in –Trp (W).  There are two clones for bait constructs CD157-pHAY1, CD157-6 
and CD157-7; two clones for bait constructs CD157-GPI- pHAY1, CD157-GPI1 and 
CD157-GPI4.  The results showed that the bait constructs were suitable to use for 
yeast two-hybrid screen in the subsequent experiment as it did not self activate the 
reporter gene in the absence of activation domain.  In order to further ensure no self-
activation of the CD157 or CD157-GPI in pHAY1 BD, a colony lift filter assay has 
been carried out according to method 2.3.6. Positive (Gal4) and negative controls 
(pHAY1) were included while performing the assay (Figure 2.6).  It was observed 
that only the positive control turn the colony into blue colors and not for the negative 
control and the bait constructs.  This further proved that the bait constructs did not 
undergo self activation and can be used to carry out the library screen.  Western blot 
has been performed to ensure the CD157 or CD157-GPI in pHAY1 BD was 




























Figure 2.5: Test for autonomous reporter gene expression in bait construct. 
 
Left panel showed the drop-out plate of –Trp (W) (upper) and –Trp/-His (WH) 
(lower) of the transformation performed in HF7c.  Right panel showed drop-out 
plate of –Trp (W) (upper) and –Trp/-Ura (WU) (lower) of the transformation 
performed in NLY21.  Two clones of CD157-GPI-pHAY1 : CD157-GPI-1 and 
CD157-GPI-4; 2 clones of CD157-pHAY1: CD157-6, CD157-7 were selected 
for the test. Positive control Y1Gal4 and negative control pHAY1 were included 
in this study. 
 
pHAY1 pHAY1 
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Figure 2.6: Colony lift filter assay 
 
1) pHAY1 plasmid (negative control) 
2) GAL4 plasmid (positive control) 





Plasmid 1-6 listed above was transformed into either HF7c or NLY21 
cells, respectively. Upper panel showed the colony lifting from HF7c 
cells whereas the lower panel showed the colony lifting from NLY21 
cell. 
Blue colony was observed for the GAL4 plasmid (positive control) 
transformed in HF7c or NLY21, but not for the pHAY1 plasmid 
(negative control), CD157-GPI and CD157 bait construct.  The 





















 HF7c cell 
NLY21 cell 
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2.4.2 Library screening 
Two bait constructs, CD157-pHAY1 and CD157-GPI-pHAY1 were used to 
screen against cDNA library from either Hela or B cell.  This is because no 
information on the interacting proteins of CD157 has been reported, therefore, the 
Hela and B cell cDNA libraries were chosen for this pilot screen.  100µg of Hela and 
B cell cDNA library that fused to pACT which is a DNA-AD was used as prey to 
screen for proteins that interact with CD157-pHAY1 or CD157-GPI-pHAY1.  Bait 
plasmid was co-transformed with the cDNA library into either NLY21 or HF7C 
competent cells (Table 2.2) and plated onto 20 plates of synthetic dropout plate.  
 
Library screen construct 
1. CD157GPI-pHAY1 + HeLa-pACT transformed in HF7c 
2. CD157-pHAY1 + B-pACT transformed in HF7c 
3. CD157-pHAY1+ HeLa-pACT transformed in NLY21 
4. CD157GPI-pHAY1 + B-pACT transformed in NLY21 
 
Table 2.2: Four different constructs that were used in the library screen of 
interacting protein for CD157 or CD157-GP1. 
 
  For transformation carried out in NLY21, the cells were spread on –Trp/-Leu/-
Ura (WLU) plates, whereas for transformation carried out in HF7c, the cells were 
spread on –Trp/-Leu/-His (WLH).  cDNA library that fused with DNA-AD carried the 
LEU2 marker, therefore it can survive in synthetic dropout plate lacking Leucine (L).  
After 3 days of incubation at 30°C, it was observed that from –Leu(L) plates there 
were 51,000 colonies in CD157GPI-pHAY1 + HeLa-pACT transformation in HF7C 
cells and 13,000 colonies in CD157-pHAY1 + B-pACT transformation in HF7C; 
110,000 colonies in CD157-pHAY1 + HeLa-pACT transformation in NLY21 and 
313,000 colonies in CD157GPI-pHAY1 + B-pACT transformation in NLY21 (results 
summarized in Table 2.3).  
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Number of colonies on  
–His (H) plate 
Library screen construct 
51,000 CD157GPI-pHAY1 + HeLa-pACT transformed in HF7c 
13.000 CD157-pHAY1 + B-pACT transformed in HF7c 
110,000 CD157-pHAY1+ HeLa-pACT transformed in NLY21 
313,000 CD157GPI-pHAY1 + B-pACT transformed in NLY21 
 
Table 2.3:  Transformation efficiency of the library screen constructs as 
observed in –His (H) plate 
 
  ~20,000- 40,000 colonies obtained from the transformation means it represents 
~105 transformations per microgram of library DNA.  Colonies that were observed in 
the drop-out plate (WLU or WLH) from the four different library screen construct 
were isolated.  Based on Table 2.4, 26 colonies were isolated from -Trp/-Leu/-Ura 
(WLU) plate of CD157-pHAY1 + HeLa-pACT transformation in NLY21 and 11 
colonies were isolated from -Trp/-Leu/-Ura (WLU) plate of CD157GPI-pHAY1 + B-
pACT transformation in NLY21.  These colonies were inoculated in –Trp/-Leu/-Ura 
(WLU) medium for the isolation of library plasmid insert.  On the other hand,  24 
colonies were isolated from -Trp/-Leu/-His (WLH) plate of CD157-pHAY1 + B-
pACT transformation in HF7C and 54 colonies were isolated from –Trp/-Leu/-His 
(WLH) plate of CD157GPI-pHAY1 + HeLa-pACT transformation in HF7C. These 
colonies were inoculated in –Trp/-Leu/-His (WLH).  In total 116 colonies were picked 
and its plasmid were isolated according to method 2.3.3. 
 
Number of colonies on 
WLU plate 
Library screen construct 
27 CD157-pHAY1+ HeLa-pACT transformed in NLY21 
11 CD157GPI-pHAY1 + B-pACT transformed in NLY21 
Number of colonies on 
WLH plate 
Library screen construct 
24 CD157-pHAY1 + B-pACT transformed in HF7c 
54 CD157GPI-pHAY1 + HeLa-pACT transformed in HF7c 
 
Table 2.4: Number of colonies isolated from library screen constructs. 
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Yeast host could not generate high copy number of plasmid; therefore, to 
generate more copy of plasmid for restriction digestion and DNA sequencing analysis 
which is important for the subsequent experiment, the plasmids isolated from yeast 
have to be transformed into DH10B.  Electrocompetent cells of DH10B were 
prepared according to method 2.3.6 and the transformation was carried out according 
to method 2.3.7 and plated on LB ampicillin plate.  A total of 116 transformations 
have been carried out. 
 
2.4.3 Confirmation of positive interactions 
In order to determine the specificity of the interaction, 3 plasmids of each 
candidate that has been propagated in DH10B was selected and re-transformed with 
its respective bait CD157-pHAY1 or CD157GPI-pHAY1 into either NLY21 or HF7c 
cell.    This is to determine the plasmid linkage of the interaction.  If the interaction of 
the candidate and bait is intact, there should be no changes of the phenotype of the 
retransformation of candidates’ plasmid with its bait.  A total of 348 plasmid isolation 
and retransformation into its bait host have been performed.  Candidates’ plasmid that 
did not show plasmid linkage was discarded (data not shown).  The remaining 
candidates that showed plasmid linkages were further confirmed its interaction with 
baits by including several controls as shown in Table 2.5.   
 
Control Constructs 
Positive Y1Gal4 + pADNS 
Negative  pHAY1 + pADNS 
Negative  pHAY1+ candidates 
Negative  CD157-pHAY1/ CD157-GPI-pHAY1 + pADNS 
 
Table 2.5: List of positive and negative controls that were used in the screen for 
positive interaction of putative candidates with CD157.  
  
 61
After 3 days of incubation at 30°C, colonies that grown on either –Trp/-Leu/-
Ura (WLU) or –Trp/-Leu/-His (WLH) that showed the correlation with the negative 
and positive controls were picked for serial dilutions assay to quantify the strength of 
protein interaction (according to method 2.3.7).  After several rounds of screening and 
selection were performed, candidates which did not produce specific positive 
phenotype after retesting were regarded as false positive and eliminated (data not 
shown).  Only the putative positive clones that gave the strong interaction in the 
dilution assay were selected for restriction digestion and sequencing.  Restriction 
digestion was used to determine whether the putative interacting proteins are all 
independent cDNAs or represent multiple isolates of a limited number of cDNAs.  
This could help to obtain profile of independent interactor which is important in the 
analysis part. Through sequencing the putative candidates, we would know the 
identity of the proteins that interact with the bait protein.  Sequencing results that 
showed candidates which were in frame with pACT (DNA-AD) and possess potential 
interaction with bait protein would be further investigated.   
Finally, only seven candidates arise from bait construct CD157-GPI-pHAY1 
screened in Hela-pACT cDNA library transformations in HF7C were identified 
cloned in-frame in pACT vector.  The seven candidates are named clone 5, 8, 17, 26, 
29, 37 and 40 respectively.  It was noted that from the sequencing result only a partial 
portion of the candidate proteins interact with the bait.  Database search was 
performed on these seven candidates to identify the protein and its possible linkage 








Candidate Amino acid region 
that interact with 
bait 
Database search result 
5(979AA) 1-430 Homo sapiens, similar to DEAD/H (Asp-Glu-
Ala-Asp/His) box polypeptide 36 
8(147AA) 1-147 Homo sapiens, calcium-regulated heat stable 
protein 
17(234AA) (31-234) Homo sapiens, proteasome (prosome, 
macropain) sununit, alpha type, 2 
26(346AA) 224-346 Homo sapiens, GPI-anchored metastasis-
associated protein homolog (C4.4A) 
29(179AA) 6-179 Homo sapiens, NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex, 9 
37(102AA) 1-102 Homo sapiens, heat shock 10kDa protein 1 
(chaperonin 10) 
40(559AA) 199-559 Homo sapiens, fuse-binding protein-interacting 
repressor (SIAHBP1), transcript variant 1 
 




Due to reasons that the identified candidates were arising from bait construct 
CD157-GPI-pHAY1, there is a possibility that GPI domain might play a role in the 
interaction with putative candidates.  Therefore, to ensure the interaction was not due 
to GPI domain, CD157-pHAY1 was used as bait to transform with these seven 
candidates again (Figure 2.7).  Subsequently, titrations were carried out in –Trp/-Leu 
(WL) and –Trp/-Leu/-His (WLH) drop-out plate to quantify the strength of the 
interaction (Figure 2.8).  The titration scoring results as observed from –Trp/-Leu/-His 





























Figure 2.7: Retransformation of candidates 5, 8, 17, 26, 29, 37, 40 
with bait CD157-pHAY1 in HF7c cells.   
The transformation were plated on the drop-out plate –Trp/-Leu/-His 
(WLH) (left panel) and Trp/-Leu (WL) (right panel) for 3 days at 
































Figure 2.8: Titration of candidates 5, 8, 17, 26, 29, 37, 40 with 
bait CD157-pHAY1 in HF7c cells.   
Titration of postive control (Y1Gal4 + pADNS), negative controls 
(pHAY1 + pADNS, pHAY1 + candidate 26, CD157-pHAY1 + 
pADNS) and candidates 5, 8, 17, 26, 29, 37, 40 with bait CD157-
pHAY1 from 0 fold till 10-6 (from right to left) was performed on 
drop-out plate –Trp/-Leu/-His (WLH) (left panel) and Trp/-Leu 
(WL) (right panel) respectively.  The plates were incubated for 3 
days at 30ºC. 
 
WLH plate  WL plate 
Y1Gal4 + pADNS 
 
pHAY1 + pADNS 
 
pHAY1 + candidate 26 
CD157-pHAY1 + pADNS 
CD157-pHAY1 + candidate 5 
 
CD157-pHAY1 + candidate 8 
 
CD157-pHAY1 + candidate 17 
 
CD157-pHAY1 + candidate 26 
 
CD157-pHAY1 + candidate 29 
 
CD157-pHAY1 + candidate 37 
 






Control positive (Y1Gal4 + pADNS) 6 
Control negative (pHAY1 + pADNS) 0 
Control negative (pHAY1 + candidate 26) 0 
Control negative (CD157-pHAY1 + pADNS) 0 
Candidate 5 + CD157-pHAY1 1 
Candidate 8 + CD157-pHAY1 2 
Candidate 17 + CD157-pHAY1 4 
Candidate 26 + CD157-pHAY1 5 
Candidate 29 + CD157-pHAY1 3 
Candidate 37 + CD157-pHAY1 1 




The titration scoring results showed that candidate 26 has the strongest 
interaction with CD157, followed by candidate 17 and 29.  However, candidate 37 
and 40 has weak interaction with CD157.  Indeed, the results obtained from the 
CD157-pHAY1 + candidates were comparable to the results from CD17-GPI-pHAY1 
+ candidate (data not shown).  This concluded the identified putative candidates in 
yeast two-hybrid were interacting with CD157 domain itself.  The identification of 
potential interacting protein of CD157 using this yeast two-hybrid approach have 
provided some useful information to further elucidate the function of CD157.  
However, the results obtained from yeast two-hybrid assays were not sufficient to 
prove the relationship of the candidate with CD157.  Therefore, the seven candidates 
were further characterized by GST pull down assay and coimmunoprecipitation study 




Table 2.7: Titration scoring of candidates + CD157-pHAY1 























Characterization of the CD157 interacting proteins through 






















Chapter 3  
 




The nucleotide sequence in the library vector pACT at XhoI restriction sites 
coding for the proteins retrieved after yeast two hybrid system screening were inserted 
in vector pGEX-5X1 (Amersham Biosciences, UK ) for expression of recombinant 
GST-tagged protein in E.coli BL21LysS cell.  The expression of GST-fusion proteins 
were used to carry out in vitro binding assay. GST pull down (Kaelin et al., 1991) is 
an affinity purification of an unknown protein from a pool of proteins in solution by 
its interaction with the GST-fusion probe protein and isolation of the complex by 
collection of the interacting proteins through the binding of GST to glutathione-
coupled beads.  However, in this study the aim is to identify interaction between the 
candidate’s GST-fusion proteins with the known protein (CD157) that is a suspected 
interactor.  The outline of the GST pull down experiment is described in Figure 3.1.  
Results from the GST pull down assay showed that the candidates 17, 26 and 29 




































Figure 3.1: Outline of a GST pull down assay. 
a) The recombinant GST-fusion protein, or control GST, is 
incubated with CD157-Fc fusion protein in the presence of 
glutathione-sepharose beads.   
b) The proteins are allowed to incubate with end-over-end mixing at 
4°C. 
c) The reaction is centrifuged to collect the GST or GST-fusion 
proteins and associated proteins (CD157-Fc). 
d) The proteins are resolved on SDS-PAGE gel and Western 
blotting.  The left panel of western blot showed the presence of 
GST and GST-fusion protein when membrane probed with anti-
GST antibody.  The right panel of Western blot showed the 
unique associations of CD157-Fc with GST-fusion protein and 







3.2.1 Oligonucleotides Synthesis 
All oligonucleotides were synthesized from PROLIGO Primers & Probes 
Forward 5 5’ gccggatcccaatgagttatgactaccat 3’ 
Reverse 5 5’ gccgcggccgctcattgtctatttacatgcc 3’ 
Forward 8 5’gccggatccccatgtcatctgagcctccc 3’ 
Reverse 8 5’gccgcggccgcctaggagctgatgacatgtc 3’ 
Forward 17 5’gccggatccagatggcggagcgcgggtac 3’ 
Reverse 17 5’gccgcggccgcttatgctatggcagccaag 3’ 
Forward 26 5’ gccggatccccatggaccccgccaggaaa 3’ 
Reverse 26 5’ gccgcggccgctcacagtaggacaccagcag 3’ 
Forward 29 5’ gccggatccccatggcgttcttggcgtcg 3’ 
Reverse 29 5’ gccgcggccgcctacatgggccgctcccggg 3’ 
Forward 37 5’ gccggatccccatggcaggacaagcgttt 3’ 
Reverse 37 5’ gccgcggccgctcagtctacgtactttccaa 3’ 
Forward 40 5’ gccggatccagatggcgacggcgaccata 3’ 
Reverse 40 5’ gccgcggccgctcacgcagagaggtcactgtt 3’ 
pGEX 5’ Sequencing primer 5’ gggctggcaagccacgtttggtg 3’ 
pGEX 3’ sequencing primer 5’ ccgggagctgcatgtgtcagagg 3’ 
 
3.2.2 Vectors 
pGEX-5X1 and pGEX-2TK were obtained from Department of Microbiology, NUS. 
 
3.2.3 Cell 
BL21LysS was obtained from Department of Microbiology, NUS. 
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3.2.4 Glutathione-S-transferase 4B  







100mM IPTG: Dissolve 500mg of isopropyl-β-D-thiogalactosidase (IPTG) in 20ml of 
distilled water. Filter-sterilize and store in small aliquots at –20°C. 
 
3.3 Methods 
3.3.1 BL21LysS Competent cell preparation 
Reagents 
TFBII solution: 10mM MOPS, 75mM Calcium Chloride, 10mM Rubidium Chloride, 
25% glycerol, pH to 6.5 with KOH, autoclave and store at 4°C. 
Procedure 
BL21LysS cells were freshly streaked from glycerol stock onto LB plate and 
incubated overnight at 37°C.  A single colony from LB plate was picked and 
inoculated in 1ml of LB medium.  Culture was incubated overnight at 37°C with 
shaking (approximately 225rpm).  On the following day, the entire overnight night 
culture was inoculated into 100ml of LB medium.  The cells were grown in a 500ml 
flask until the A600 reaches 0.4-0.6.  Cell was pelleted down by centrifugation at 2.5k 
x g for 15 minutes at 4°C.  Cell pellet was gently resuspended in 10ml cold TFBII 
solution and incubated on ice for 30 minutes.  Competent cells were aliquoted into 
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pre-chilled sterile eppendorf tube and store at -80°C.   
 
3.3.2 Preparation of LB/Chlamphenicol/ Ampicillin plate 
LB/Chlamphenicol/Ampicillin plate per liter contained 10% Tryptone, 5% Yeast 
Extract, 5% Sodium Chloride and 15g Bacto agar.  Medium was autoclaved and 
allowed to cool to 55°C before adding 40mg/l of chloramphenicol and 100ug/ml of 
ampicillin. 30-35ml of medium was poured into 85mm petri dishes.  Agar was 
allowed to harden overnight and stored at 4°C for less than a month. 
 
3.3.3 Protein expression of GST fusion protein 
Reagents 
100mM IPTG, 1X cold PBS, LB ampicillin medium, DNase, 1M MgCl2 
Procedure  
Single colony was picked from LB/ Chlamphenicol/ Ampicillin plate and inoculated 
into 3ml LB ampicillin medium.  Culture was incubated overnight at 37°C on a 
shaker.  500µL of the overnight culture was then inoculated into 50ml LB ampicillin 
medium (1:100 dilutions) and allowed to grow till A600 reach 0.5-1.0.  Culture was 
induced with IPTG at final concentration of 0.1mM.  Then, culture was allowed to 
grow for another 4 hours before harvesting the protein.  After 4 hours of induction 
time, cell was spun down at 5krpm for 15 minutes at 4°C.  Cell pellet was 
resuspended in 5ml cold 1XPBS and kept at –80°C.  After freezing for few hours at –
80°C, cell lysate was taken out and thawed at room temperature.  The freeze thawed 
cycles was then repeated for one time more.  At the final freeze thawed cycle, 2.5µL 
of DNase (7.9µg/ml) and 25µL of 1M MgCl2 was added to the cell lysate and 
incubated at room temperature for 30 minutes.  Cell debris was spun down at 5krpm 
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for 15 minutes at 4°C.  Supernatant was then transferred to a new tube and kept at -
80°C.  An aliquot of supernatant was subject to SDS-PAGE and Coomassie staining 
to check for protein expression of the GST fusion protein. 
 
3.3.4 GST pull down assay 
Reagents 
 
Glutathione Sepharose 4B 
1XPBS 
Binding buffer: 50mM Tris-HCl, pH7.4, 1mM EDTA, 1mM EGTA, 150mM NaCl, 
0.5% Triton X-100, protease inhibitors (1mM PMSF, 2µg/ml leupeptin, 10µg/ml 
aprotinin, 50µg/ml SBT1) 
Procedure 
1.33ml of the 75% Glutathione Sepharose 4B was pipetted into a 15ml falcon tube 
and subjected to centrifugation at 500 x g for 5 minutes.  The sedimented glutathione 
sepharose was washed in 10ml cold 1xPBS and subjected to centrifugation at 500g for 
5 minutes to wash off the 20% ethanol storage solution.  Then, 1ml PBS was added to 
the washed glutathione sepharose.  This results in 50% slurry to be used in the 
subsequent purification step.   In order to purify GST proteins from the 400ml of 
culture medium, 200µL of the 50% glutathione sepharose bed volume was needed.  
Following that, 400µL of the 50% glutathione sepharose 4B slurry (bed volume was 
equal to 0.5X the volume of the 50% slurry used) was poured into the cell lysate and 
incubated in cold room for one and the half hour.  Suspension was centrifuged at 500 
x g for 5 minutes and the glutathione pellet was washed with 10 bed volume of 
1XPBS.  Suspension was centrifuged at 500g for 5 minutes to sediment the matrix.  
The washing step was repeated two more times.  Glutathione sepharose 4B now was 
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coupled with GST fusion protein and was used to bind with CD157-Fc fusion protein 
(1µg) in binding buffer for 2 hours in cold room.  Suspension mix then was 
centrifuged at 500g for 5 minutes and washed with 10 bed volumes of 1XPBS.  The 
washing step was repeated two more times.  Sediment that contained glutathione 
sepharose which couple with the interacting protein was run on SDS-PAGE for 
Coomassie staining and Western blotting detection. 
 
 
3.3.5 Stripping and reprobing of nitrocellulose membrane 
 
Reagents 
Stripping buffer: 100mM 2-mercaptoethanol, 2% SDS, 62mM Tris-HCl, pH 6.7 
1XTBST: 100mM Tris, 300mM NaCl, 0.1% Tween-20. 
Procedure 
Submerge the nitrocellulose membrane in stripping buffer and incubate at 50°C for 30 
minutes with occasional agitation.  Membrane was washed with 1XTBST for 5 
minutes.  The washing step was repeated two more times.  Membrane was then 
blocked with 1% casein for 1 hour and the immunodetection method was repeated 










3.4 Results and Discussions 
3.4.1 Cloning of putative candidates into pGEX expression vector 
Putative candidates that showed interactions with CD157 in the yeast two-
hybrid screens were further characterized in in vitro binding assay.  The nucleotide 
sequence in the library vector pACT at XhoI restriction sites coding for the 
candidates’ proteins were amplified  from the Hela cDNA library using PCR approach 
and cloned into pGEX-5X1 vector that could express N-terminal GST fusion protein.  
pGEX expression vectors contain a tac promoter for chemically inducible, high level 
protein expression.  The vector has an open reading frame encoding glutathione-S-
transferase (GST) followed by termination codons.  Figure 3.2 showed the schematic 
diagram of the cloning approach. 
 The coding region of each candidate was amplified from cDNA library of 
Hela cell line according to method 1.3.1 using its respective forward and reverse 
primers, which listed on the material 3.2.1.  It was noted that the annealing 
temperature to carry out the PCR for candidates 26 and 29 were 65°C, for candidates 
8, 17, 37 were 60°C, for candidate 40 was 55°C and candidate 5 was 50°C.  Figure 
3.3 showed the electrophoresed PCR product of the putative candidates on 1% 
agarose gel as prepared according to method 1.3.2.  In Figure 3.3a, it showed 1289bp 
of candidate 5; Figure 3.3b, showed 441bp of candidate 8 and 702bp of candidate 17; 
Figure 3.3c, showed 1038bp of candidate 26 and 537bp of candidate 29; Figure 3.3d, 
showed 306bp of candidate 37 and 1677bp of candidate 40.  PCR product of each 
candidate was purified according to method 1.3.3 and subjected to restriction enzyme 
digestion using BamHI and NotI according to method 1.3.4.  The digested DNA 
fragments were ligated into BamHI and NotI sites of pGEX-5X1 vector according to 
method 1.3.5.  The ligation mix was then transformed into DH5α and plated onto 
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Figure 3.2: Schematic diagram of cloning approach of candidates (5, 8, 17, 
26, 29, 37 and 40) into GST vector. 
Candidates 5,8,17,26,29,37 and 40 were cloned into the BamHI and NotI site 















Figure 3.3: Electrophoresis 
of PCR products on 1% 
agarose gel 
 
a: PCR product of candidate 5 
(1289bp) from Hela cDNA 









b: PCR product of candidate 8 
(441bp) and 17 (702bp) from 
Hela cDNA using primers 
Forward 8, Reverse 8 and 









c: PCR product of the 
candidate 26 (1038bp) and 29 
(537bp) from Hela cDNA 
using primers Forward 26, 
Reverse 26 and Forward 29 






d: PCR product of the 
candidate 37 (306bp) and 29 
(537bp) from Hela cDNA 
using primers Forward 26, 
Reverse 26 and Forward 29 










After overnight incubation at 37°C, colonies were observed on the ampicillin 
selection plates.  Several clones were picked for plasmid isolation according to 
method 1.3.9.  Positive clones were verified by restriction digestion (method 1.3.4) 
and sequencing according to method 1.3.10.  The correct clones for candidates 5, 8, 
17, 26, 29, 37, 40 which fused N-terminally with GST were later re-transformed into 
BL21LysS competence cell according to method 3.3.1.  Transformation was plated on 
LB/Choramphenicol/Ampicillin plate and incubated at 37°C overnight.  BL21LysS 
contained an episomal chlamphenicol which can inhibit protein synthesis.  Therefore, 
the GST fusion protein will only start its expression in BL21LysS when cell reaches 
A600 ~ 1.0 and induced by 0.1mM of IPTG.  The BL21LysS cell has been modified 
that it has lysozyme that could lysed the cell wall by simply freezing and thawing 
methods.  Therefore, the GST fusion protein could be easily harvested from the cell 
lysate.   
 
3.4.2 GST protein expression 
Colony was picked from the LB/Choramphenicol/Ampicillin plate and grown 
in LB ampicillin medium.  Cells were induced with isopropyl-1-thio-b-D-
galactopyranoside (IPTG) to express the desired fusion protein according to method 
3.3.4.  After 4 hours of induction, the cells were harvested and run on the SDS-PAGE 
gel.  The expression of GST fusion protein was detected by Coomassie blue stain 
(method 1.3.17) and Western blotting according to method 1.3.18 using anti-GST 
monoclonal antibody as primary antibody and anti-mouse HRP antibody as the 
secondary antibody.  Figure 3.4 showed the expressed GST fusion proteins from each 
candidate.  The molecular weight of the expressed proteins for each candidate was 































Table 3.1: List of molecular weight (kDa) for candidate-GST fusion proteins 
and GST vector. 
 
GST        40             37         29        26         17          8              5 
Figure 3.4: Western blot analysis of GST and GST-fusion protein (5, 8, 
17, 26, 29, 37 and 40) expression. 
Expressed protein were harvested and resolved in 12% SDS-PAGE 
followed by transfer onto nitrocellulose membrane.  Membrane was then 






3.4.3 In vitro binding assay 
Expressed GST fusion protein was used for in vitro binding assay according to 
method 3.3.5.  Interacting protein was detected in Western blotting using anti-GST 
monoclonal antibody as primary antibody and anti-mouse HRP antibody as the 
secondary antibody.  Membrane was stripped and reprobed with goat anti-CD157 as 
primary antibody and anti-goat HRP as secondary antibody.  It was observed from the 
GST pull down assay that candidate 17 and 26 shown interaction with CD157 (see 
Figure 3.5). GST pull down assays characterize in vitro interactions, the specificity of 
the interaction between candidate 17 and 26 with CD157 will subsequently be 










































      +               +                +                +     anti-GST  
 
 GST vector     29             26               17 
             -               +                +                 +       anti-CD157  
Figure 3.5:  CD157 interacts with candidate 17, 26 and 29 in 
GST pull down assay. 
 
Upper panel showed the ectopic expression of GST and GST-
fusion protein of candidate 17, 26 and 29 in E.coli.  The cell 
lysates were subjected to 12% SDS-PAGE followed by Western 
blot with anti-GST antibody.  The + sign indicated the expression 
of GST-fusion protein. 
 
Lower panel showed the CD157-Fc fusion protein coprecipitated 
with candidate 17, 26 and 29 in in vitro binding assay. 
CD157-Fc recombinant protein was incubated with GST, GST-
candidate 17, GST-candidate 26 and GST-candidate 29 
immobilized on glutathione-sepharose beads.  After the beads 
were washed, retained CD157 was subjected to 12% SDS-PAGE 
followed by Western blot analysis with anti-CD157 antibodies. 
CD157-Fc fusion protein was able to be pulled down by 29-GST, 


























































Immunoprecipitation, involves the precipitation of a molecule, usually a 
protein, from a crude mixture of other proteins and biological molecules, often a cell 
or tissue homogenate, using an antibody to the protein of interest and a mean of 
precipitating the complex to allow its separation from the initial mixture.  If protein X 
is immunoprecipitated with an antibody to X, then protein Y, which is stably 
associated with X in vivo, may also precipitate.  This precipitation of protein Y, based 
on a physical interaction with X, is referring to as coimmunoprecipitation.  This 
approach is most commonly used to test whether two proteins of interest are 
associated in vivo. The outline of the coimmunoprecipitation is described in Figure 
4.1.  In chapter 3, potential candidates that showed interaction with CD157 in GST 
pull down were further tested in coimmunoprecipitation study.  Candidates that 
expressed N-terminal myc fusion proteins in CD157-Fc CHO stable cells were 
analyzed.  It was observed that candidate 17 showed the interaction with CD157.  The 
Blast search result identified that candidate 17 is a proteasome protein.  Proteasome 
plays an important role in the non-lysosomal degradation of intracellular proteins, in 
antigen processing and in cellular regulation through the degradation of short-lived 
regulatory proteins.  The discovery of interaction of CD157 with proteasome might 






























Figure 4.1: Outline of detection of proteins by 
coimmunopecipitation. 
In the intact cell, protein X is present in a complex with protein 
Y.  This complex is preserved after cell lysis and allows protein Y 
to be coimmunoprecipitated with protein X. 
A: Intracellular; B: Extracellular 
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4.2 Materials 
4.2.1 Oligonucleotides Synthesis 
All oligonucleotides were synthesized from PROLIGO Primers & Probes 
N-myc 17  5’ gccgtcgaccatggcggagcgcgggta 3’ 
Rev_17-2  5’ gccgcggccgcttatgctatggcagccaag 3’ 
N-myc 26  5’ gccgtcgaccatggaccccgccaggaaa 3’ 
#26-1 Reverse  5’ gccgcggcgcgtcacagtaggacaccagcag 3’ 
N-myc 29  5’ gccgtcgaccatggcgttcttggcgtcg 3’ 
#29-1 Reverse  5’ gccgcggccgcctacatgggccgctcccggg 3’ 
 
4.2.2 Vector 
pCMV-Myc mammalian expression vector was purchased from Clontech, USA.  
 
4.3 Methods 
4.3.1 Transient transfection of recombinant myc-fusion construct into 
CHO/CD157-Fc stable cell 
Reagents 
1. Lipofectamine 
2. Plasmid  
3. Opti-MEM 




1.8 x 105 CHO/CD157-Fc cells were seeded in a 75cm2 flask in 15ml RPMI complete 
medium.  Cells were incubated at 37°C in a CO2 incubator until the cells were 50-
80% confluent.  The following solutions were prepared in 12 X 75mm sterile tubes: 
Solution A: 8µg of plasmid was diluted into 500µL Opti-MEM 1 serum free medium.  
Solution B: 24µL of Lipofectamine was diluted into 500µL Opti-MEM 1 serum free 
medium.  Solution A and B were combined, mixed gently and incubated at room 
temperature for 45 minutes to allow DNA-liposome complexes to form.  While 
complexes formed, cells were rinsed once with serum-free medium.  DNA-liposome 
complexes were gently mixed and overlaid onto the rinsed cells in 15ml opti-MEM.  
Cells were incubated with the complexes for 7 hours at 37°C in a CO2 incubator then 
changed to RPMI complete medium.  Transfected cells were allowed to express 
proteins for 48 hours. 
 
4.3.2 Immunoprecipitation using adherent cells lysed with a non-ionic detergent 
solution 
Reagents 
1. Ice cold nondenaturing lysis buffer:1% (w/v) Triton X-100, 50mM Tris-HCl, 
pH7.4, 300mM NaCl, 5mM EDTA, 10mM iodoacetamide, 1mM PMSF, 
2ug/ml leupeptin. 
2. Anti-myc agarose conjugate (Sigma, USA) 
3. Ice cold PBS with protease inhibitor: 1mM PMSF, 2µg/ml leupeptin, 10µg/ml 
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aprotinin, 50µg/ml SBT1 
4. Ice cold PBS 
5. Ice cold washing buffer: 0.1% (w/v) Triton X-100, 50mM Tris-HCl, pH 7.4, 
300mM NaCl, 5mM EDTA 
Procedure 
Transfected cells in tissue culture flask were rinsed twice with ice-cold PBS.  PBS 
was then removed by aspiration with a Pasteur pipet attached to a vacuum pump.  Ice 
cold PBS buffer with protease inhibitor was added to the tissue culture flask and cells 
were scraped off from the flask with a rubber policeman.  Suspension was then 
transferred to a 1.5ml eppendorf tube and centrifuged at 14krpm for 1 minute at 4°C.  
1ml of the non-denaturing lysis buffer was then added to the cell pellet and mixed 
well.  The cell lysate was kept on ice for 30 minutes.  Lysate was then cleared by 
centrifugation at 14krpm for 15 minutes at 4°C.  Supernatant was then transferred to a 
fresh tube and keep on ice.  50µl of anti-myc agarose conjugate was then added to the 
cleared lysate and incubated overnight over a rotator mixer in the cold room.  The 
bound proteins on the myc-agarose beads were pelleted down by centrifugation at 
14krpm for 5 seconds at 4°C.  Supernatant containing the unbound proteins were 
aspirated out.  Then 1ml of ice cold wash buffer was added to the beads and tubes 
were inverted for few times.  Beads were then pelleted down by centrifugation at 
14krpm for 5 seconds.  The washing step was repeated twice.  The beads were washed 
once more with 1ml ice cold PBS and beads were then pelleted down by 
centrifugation at 14krpm for 5 seconds.  SDS loading buffer was then added to the 
washed beads and run on the SDS-PAGE.  Western blot was then carried and detected 
using monoclonal anti-myc antibody (Sigma, USA). 
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4.4 Results and Discussion 
In order to study the in vivo interaction of proteins with CD157, candidate’s 
fragment was fused to a myc tag using pCMV-Myc tag mammalian expression vector 
for the coimmunoprecipitation study.  Full length fragments of candidates were 
amplified from the Hela cDNA using its respective forward and reverse primers as 
listed in material 4.2.1.  PCR were carried out according to method 1.3.1 at the 
annealing temperature of 55ºC.  Primers N-myc 17, Rev_17-2 were used to PCR 
candidate 17; primers N-myc 26, #26-1 Reverse were used to PCR candidate 26; 
primers N-myc 29, #29-1 Reverse were used to PCR candidate 29.  Figure 4.2 showed 
the results of the PCR product which amplified a 700bp of candidate 17, 1041bp of 










Figure 4.2: Electrophoresis of PCR product on 1% agarose gel. 
Lane 1: Candidate 17 (700bp) 
Lane 2: Candidate 26 (1041bp) 
Lane 3: Candidate 29 (540bp) 
      1kb DNA     1      2             3 
      marker 
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PCR fragments were then purified according to method 1.3.3.  The purified 
PCR fragment of each candidate and pCMV-Myc vector were subjected to restriction 
enzyme digestion using SalI and NotI enzymes according to method 1.3.4.  The 
restriction digested product of the candidates fragment and vector (see Figure 4.3) 
were then purified and subjected to ligation according to method 1.3.5.  
Transformation were then carried out as according to method 1.3.8 and plated on LB 
Ampicillin plate.  The schematic diagram of the cloning approach was shown in 









Figure 4.3: Electrophoresis of restriction digested products by 
SalI and NotI enzymes on 1% agarose gel. 
 
Lane 1: Candidate 17 (700bp),  
Lane 2: Candidate 26 (1041bp)  
Lane 3: Candidate 29 (540bp)  
Lane 4: pCMV-Myc vector (3.8kb) 
1kb DNA     1          2           3            4  
marker    






After overnight incubation of the transformation, colonies were observed on 
the selection plate.  Several colonies were picked for plasmid isolation (method 1.3.9) 
and subjected to PCR screen and restriction enzyme digestion.  Clones that showed 
the correct size from the PCR and digestion screen were then subjected to DNA 
sequencing (method 1.3.10), to ensure that the picked clones were the correct ones 
before carrying out the subsequent experiments.  Sequencing results showed the 
candidates 17, 26 and 29 were cloned in frame with the pCMV- Myc vector (data not 
shown).  Large scale plasmid purification (Midiprep) was carried out as described in 
method 1.3.11 to prepare plasmid stock for each candidate for transfection into 
mammalian cells.  Expression of the myc-tag fusion protein for each candidate was 
analysed in CHO/CD157-Fc cells.  Transient transfection of the myc-tag candidates 
Figure 4.4: Schematic diagram of cloning approach of 
candidate 17, 26 and 29 into pCMV-myc vector. 
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were carried according to method 4.3.1, proteins were harvested and subjected to 
immunoprecipitaion according to method 4.3.2.  Immunoprecipitation results showed 
that myc-tag candidate 17 has a very good expression in Cos-7; however, weak 
expression of myc-tag candidate 29, and no expression of myc-tag candidate 26 (see 









No expression of candidate 26 in this transient transfection study was probably 
due to the reason that N-terminal myc tag does not allow the expression of candidate 
26.  It was known from the database search that candidate 26 is a GPI metastasis-
associated protein homolog (C4.4A) as identified in yeast two-hybrid screen from 
Chapter Two which possess an N-terminal targeting sequence.  Therefore, by putting 
a tag protein at its N-terminal may disrupt the expression of protein.  Candidate 26 
with a C-terminal myc tag was reconstructed and it showed a good expression in the 
CHO/CD157-Fc cell (data not shown).  This candidate 26 which expressed C-terminal 
Figure 4.5:  Ectopic expression of recombinant myc-candidate 
fusion protein in CHO/CD157-Fc cells.   
Recombinant myc-candidates and control were transfected into 
CHO/CD157-Fc cells and the expressed proteins were 
immunoprecipitated by myc-agarose.  After the beads were washed, 
retained myc-candidate proteins were subjected to 12% SDS-PAGE, 
followed by Western blot analysis with anti-myc antibody.  
29-myc           26-myc        17-myc         vector only 
control 
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myc tag was used to carry out the coimmunoprecipitation study.  However, results 
showed that it does not have any interaction with CD157.  
Coimmunoprecipitation is most commonly used to test whether two proteins 
of interest are associated in vivo.  Detection of an interaction by this method requires 
that the protein-protein complex remain intact through a series of wash step.  
Therefore, low-affinity and transient interactions that exist in the cell in a state of 
dynamic equilibrium may not be observed with this method.  Moreover, this approach 
is only applicable to proteins that persist in physiological complexes after they have 
been solubilized from the cell.  Thus, it may not be appropriate for detection of 
protein-protein interactions that make up large, insoluble macromolecule structures of 
the cell, example, nuclear and extracellular matrices. Therefore, it was possible that 
candidates 26, GPI-anchored metastasis-associated protein homolog (C4.4A), which 
detected in GST pull down, was not able to be detected in coimmunoprecipitation.  
For the other two potential interacting candidates, 17 and 29 which fused N-
terminally to myc-tag protein were transfected into CD157-Fc CHO stable cell 
respectively for coimmunoprecipitation study.  Cells were lysed according to method 
4.3.2 and pull down by anti-myc agarose.  The presence of the CD157-Fc fusion 
protein was detected by anti-CD157 antibody.  Figure 4.6 showed that Myc-candidate 
17 fusion protein has the interaction with CD157-Fc, as CD157-Fc was able to be pull 
down by anti-myc agarose.  Candidate 17 was identified as a proteasome (prosome, 
macropain) subunit.  However, the ability to coprecipitate two proteins from a cellular 
extract is not proof that a particular interaction normally takes place in vivo.  
Therefore, to further conclude the interaction of CD157 with proteasome, future 





























               








Figure 4.6: Coimmunoprecipitation of candidate 17 with CD157. 
Myc-tagged candidate 17, 29 and pCMV vector (control) were co-
transfected into CHO/CD157-Fc cells.  After 48 hours post-transfection, 
coimmunoprecipitation and Western analysis were carried out.   
(A) Immunoprecipitation with anti-myc antibody, Western analysis with 
anti-CD157.   
(B) 1/6 of the cell lysate was subjected to western analysis before 
immunoprecipitation to demonstrate the expression of transfected 
plasmid.  Anti-myc antibody was used to show the expression of 
myc-tagged candidate’s fusion protein. 
(C) anti-CD157 antibody was used to show the constitutive expression 
of CD157-Fc in CHO/CD157-Fc.   




























Approximately a third of the predicted proteins of an organism are anchored in 
the lipid bilayer from the complete genome sequence (Goffeau et al., 1996; Auerbach 
et al., 2002).  These membrane associated proteins perform a wide range of essential 
cellular functions.  For example, pores, channels, pumps and transporters facilitate the 
exchange of membrane-impermeable molecules between cellular compartments and 
between a cell and its extracellular environment.  Transmembrane receptors, sense 
changes in the cellular environment and, typically through associated proteins, initiate 
specific responses.  Because of their accessibility and essential roles, membrane 
proteins are also of considerable diagnostic and therapeutic importance: 50% of 
currently known drug targets (~500) are either membrane receptors or ion channels 
(Reiss 2001).  Thus, understanding the physiology of membrane proteins and the 
means by which these proteins communicate in the cells is of crucial importance. 
Protein interactions are involved in the regulation and execution of all 
biochemical pathways within the cell.  Thus, the identification of binding partners for 
CD157 is important to further elucidate its function.  Therefore, yeast two-hybrid 
approach has been employed in search of the interacting protein(s) of CD157.  Even 
though, the yeast two-hybrid technique has been used to study numerous intracellular 
protein associations (Chein et al., 1991; Durfee et al., 1993; Wade Harper et al., 1993; 
Li et al., 1993; Yang et al., 1992), some membrane proteins have been successfully 
expressed as a partial extracellular or intracellular domain and shown to interact with 
their specific ligand or partner. (Ozenberger and Young 1995; Keegan and Cooper 
1996; Bourette et al, 1997; Hellyer et al., 1998; Borg et al., 2000). Appropriate 
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extracellular receptor-ligand interactions have been shown for growth hormone and 
prolactin (Ozenberger and Young 1995).  The system has been proven to work 
because the extracellular domain used as bait contains whole critical ligand-binding 
determinants.  Using the cytoplasmic domain of the platelet-derived growth factor 
receptor as bait, it interacts with and phosphorylates SHPTP2, a ubiquitously 
expressed SH2-containing tyrosine phosphatase, allowing the interaction of the 
phosphorylated SHPTP2 with the signaling protein Grb7 (Keegan and Cooper 1996).  
The traditional yeast two-hybrid procedure has been used to identify new proteins 
interacting with the ErbB2 receptor (Borg et al., 2000).  Using only the nine carboxyl 
terminal residues of the intracellular domain of ErbB2 as bait, a new PDZ protein 
ERBIN (ErbB2 interacting protein) that acts as an adaptor for the receptor in epithelia 
has been identified.   
In this study, the soluble CD157 (without the GPI domain) was used as bait in 
yeast two-hybrid screening against Hela and B cell cDNA libraries.  It was found that 
Homo sapiens, proteasome (prosome, macropain) subunit, alpha type-2 interact with 
CD157 (see Chapter 2).  In order to test the specificity of interaction, we later 
expressed a 74kDa CD157-Fc fusion protein (containing the human IgG1 Fc region) 
(see Chapter 1) and proteasome-GST fusion protein for in vitro binding assay.  
Western blotting result showed the interaction was intact in this GST pull down assay 
(see Chapter 3).  The specificity of the interaction of CD157 with proteasome was 
further characterized by over expressing proteasome-myc tag protein in CD157-Fc 
CHO stable cell line for coimmunoprecipitation study (see Chapter 4).  The results 
showed that proteasome interacts with CD157. 
Analysis of the full length cDNA sequence of proteasome subunit, alpha type-
2 revealed an open reading frame of 704bp, encoding a predicted protein of 234 
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amino acid residues of 26kDa.  Proteasome (26S) comprises of two subcomplexes, the 
20S core particle and one or two regulatory complexes, the 19S caps (Tanaka, 1998; 
DeMartino and Slaughter, 1999; Gorbea and Rechsteiner, 2000).  The core structure 
(20S) is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 
alpha (α) subunits and 2 rings are composed of 7 beta (β) subunits.  The active sites 
reside in three β subunits, β1, β2, β5, but not in the α subunits (Seemuller et al., 1995).  
The α subunits, however, may play an essential role in stabilizing the two β ring 
structures and also in the binding of the 19S cap complexes (Groll et al., 1997).  The 
26S proteasome, is responsible for the bulk turnover of cytoplasmic and nuclear 
proteins in eukaryotic cells and also plays a key role in the regulation of cell cycle, 
signal transduction, transcription as well as antigen presentation (Coux et al., 1996; 
Hayashi et al., 1996; Chen et al., 1996; Pickart 1997; Tanaka et al., 1998).   
Proteasomes are distributed throughout eukaryotic cells at a high 
concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-
lysosomal pathway.  Ubiquitin is a highly conserved 76 amino-acid polypeptide 
(Hochstrasser, 1996).  It attached to a target protein by an isopeptide bond formed 
between the epsilon-amino group of lysine on the target and the C-terminal glycine 
residue of ubiquitin by a series of ubiquitin conjugating enzymes, E1, E2 and E3.  The 
E1 protein activates ubiquitin by hydrolyzing ATP and forming a covalent attachment 
with ubiquitin.  The E1 protein transfers the activated ubiquitin to E2.  The enzyme 
E3 determines which proteins will be degraded for destruction and transfer the 
ubiquitin from E2 to the target protein.  It has become apparent that the polypeptide 
ubiquitin is a key participant in the down-regulation of many plasma membrane 
proteins (Hicke, 1999).   
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A number of plasma membrane proteins in Saccharomyces cerevisiae and 
animal cells have been modified by ubiquitin (Hicke, 1997; Bonifacino and Weissman 
1998).  In yeast ubiquitination serves to trigger the internalization of plasma 
membrane proteins into the endocytic pathway.  This leads to their degradation in the 
vacuole.  However, in animal cell, the situation is not as clear because a number of 
plasma membrane proteins that are ubiquitinated appeared to be degraded through 
both the proteasome and lysosomal pathway.  For example, the tyrosine kinase 
receptor or kinase-linked receptor for EGF, PDGF and GH that undergo ligand-
stimulated ubiquitination at the plasma membrane are internalized and degraded 
(Mori et al., 1992; Strous et al., 1996; Galcheva-Gargova et al., 1995). Protein 
ubiquitination is a post-translational modification which plays a major role in 
regulated degradation of cellular proteins. There is a possibility that CD157, also 
undergo this process.  It was observed that the multiplicity of signals that target 
proteins for degradation is underscored by the phosphorylation, which prevents their 
degradation.  The phosphorylation of the c-Mos proto-oncogen on Ser3 and the 
multiple phosphorylation of c-Fos and c-Jun proto-oncogenes by mitogen-activated 
protein (MAP) kinase suppress their ubiquitination and degradation (Nishizawa et al., 
1992; Okazaki et al., 1995; Musti et al., 1997).  The CD157 that undergo downstream 
tyrosine phosphorylation signaling may also have the possibility of protein 
degradation inhibition function.  Therefore, examination of the role of ubiquitin 
pathway in CD157 degradation may help to provide better understanding of the 
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